CN1915995A - S type 4-substituted hydroxy-pyranindolelidinyl compounds and its derivatives and production method - Google Patents

S type 4-substituted hydroxy-pyranindolelidinyl compounds and its derivatives and production method Download PDF

Info

Publication number
CN1915995A
CN1915995A CNA2006101011920A CN200610101192A CN1915995A CN 1915995 A CN1915995 A CN 1915995A CN A2006101011920 A CNA2006101011920 A CN A2006101011920A CN 200610101192 A CN200610101192 A CN 200610101192A CN 1915995 A CN1915995 A CN 1915995A
Authority
CN
China
Prior art keywords
compound
mile
group
type
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CNA2006101011920A
Other languages
Chinese (zh)
Other versions
CN100528879C (en
Inventor
川口隆行
野村纯宏
辻原健二
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Tanabe Pharma Corp
Original Assignee
Tanabe Seiyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co Ltd filed Critical Tanabe Seiyaku Co Ltd
Publication of CN1915995A publication Critical patent/CN1915995A/en
Application granted granted Critical
Publication of CN100528879C publication Critical patent/CN100528879C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14Ortho-condensed systems
    • GPHYSICS
    • G02OPTICS
    • G02FOPTICAL DEVICES OR ARRANGEMENTS FOR THE CONTROL OF LIGHT BY MODIFICATION OF THE OPTICAL PROPERTIES OF THE MEDIA OF THE ELEMENTS INVOLVED THEREIN; NON-LINEAR OPTICS; FREQUENCY-CHANGING OF LIGHT; OPTICAL LOGIC ELEMENTS; OPTICAL ANALOGUE/DIGITAL CONVERTERS
    • G02F1/00Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics
    • G02F1/01Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics for the control of the intensity, phase, polarisation or colour 
    • G02F1/13Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics for the control of the intensity, phase, polarisation or colour  based on liquid crystals, e.g. single liquid crystal display cells
    • G02F1/133Constructional arrangements; Operation of liquid crystal cells; Circuit arrangements
    • G02F1/1333Constructional arrangements; Manufacturing methods
    • G02F1/1345Conductors connecting electrodes to cell terminals
    • G02F1/13452Conductors connecting driver circuitry and terminals of panels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • GPHYSICS
    • G02OPTICS
    • G02FOPTICAL DEVICES OR ARRANGEMENTS FOR THE CONTROL OF LIGHT BY MODIFICATION OF THE OPTICAL PROPERTIES OF THE MEDIA OF THE ELEMENTS INVOLVED THEREIN; NON-LINEAR OPTICS; FREQUENCY-CHANGING OF LIGHT; OPTICAL LOGIC ELEMENTS; OPTICAL ANALOGUE/DIGITAL CONVERTERS
    • G02F1/00Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics
    • G02F1/01Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics for the control of the intensity, phase, polarisation or colour 
    • G02F1/13Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics for the control of the intensity, phase, polarisation or colour  based on liquid crystals, e.g. single liquid crystal display cells
    • G02F1/1303Apparatus specially adapted to the manufacture of LCDs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Abstract

The present invention relates to an S type 4-substituted hydroxypyrano-indolidine compound and a process for preparing the same. More exactly, the present invention relates to a method for preparing S type 2-substituted hydroxypyrano-indolidine compound of the midbody of camptothecin derivative which has an anticancer activity at a high yield and a high stereoselectivity.

Description

S type 4-type 4-substituted hydroxy-pyranindolelidinyl compounds and its derivative with and preparation method thereof
Present patent application is that Chinese patent application number is 01110958.0, the applying date is on October 30th, 1997, denomination of invention is divided an application for the Chinese patent application of " S type 4-type 4-substituted hydroxy-pyranindolelidinyl compounds and its derivative and its preparation method ".
The present invention relates to S type 4-type 4-substituted hydroxy-pyranindolelidinyl (indolidine) compound or its salt or derivatives thereof with and preparation method thereof.More precisely, the method that the present invention relates to be used as the S type 4-type 4-substituted hydroxy-pyranindolelidinyl compounds of the intermediate for preparing camptothecin derivative and prepare this compound with high yield and highly-solid selectively with antitumour activity.
Known by Friedlaneder reaction (referring to EP-A-540099, EP-A-296597, JP-A-6-87746, WO 90/0169, EP-A-418099) preparation has the method for the camptothecin derivative of antitumour activity, has wherein discovered the method that is used to prepare as formula [VIII] the S type 4-hydroxyl Pyranoindole mile acridine compound of important intermediate:
Figure A20061010119200151
In addition; according to report the bromination on 2 of through type [XX] the 2-indoles mile pyridine yl acetate chemical combination among the EP-A-220601 for example and make this reaction product with (R)-reaction of N-tosyl group proline(Pro) can preparation formula [XXI] S type 2-[(R)-N-tosyl group-prolyl oxygen base]-2-indoles mile pyridine base butyric ester compound; and report also by this compound and prepare the derivative of camptothecine that its Chinese style [XXI] and formula [XX] are as follows through formula [VIII] S type 4-hydroxyl Pyranoindole mile acridine compound:
But; according to this method; can only obtain 2 purpose formula [XXI] the S type 2-[(R that go up the high 2.6-4.6 of diastereomer output times (44-64%d.e.) of " R " absolute configuration that have than preparation simultaneously)-N-tosyl group-prolyl oxygen base]-2-indoles mile pyridine base butyric ester compound; thus, and classified crystallization (referring to Organic Synthetic Chemistry, 49 volumes; 11 phases; the 1013-1020 page or leaf, 1991) yield of isolating described S type compound is lower, has only 56%.
The present invention provides S type 2-substituted hydroxy-2-indoles mile pyridine base butyric ester compound of the intermediate that is used as the preparation camptothecin derivative with high yield and highly-solid selectively.
According to the present invention, through type [III] 2-halo-2-indoles mile pyridine yl acetate compound and nitrogenous annelated heterocycles carboxylic acid cpd of formula [IV] R type or its reactant salt, production [I] 2-substituted hydroxy-2-indoles mile pyridine yl acetate compound, make 2 of formula [I] resultant to go up ethylizations and can prepare purpose formula [II] S type 2-substituted hydroxy-2-indoles mile pyridine base butyric ester compound then, its Chinese style [II], [III], [IV] and [I] are as follows:
Figure A20061010119200171
Wherein, X is a halogen atom, R 1And R 2Be low alkyl group, reaching E is the ester residue,
R 0OH [IV]
R wherein 0Be the residue of nitrogenous annelated heterocycles carboxylic acid with absolute configuration " R ", it is to remove (wherein, the nitrogen-atoms in described residue is protected) that obtains behind the hydroxyl on the carboxyl by this carboxylic acid cpd,
Figure A20061010119200172
Symbol wherein as defined above.
The inventive method is characterised in that formula [I] 2-substituted hydroxy-2-indoles mile pyridine yl acetate compound is big at its acetal part steric barrier, and on its 2, has the big substituting group of steric barrier that comprises optically active nitrogenous annelated heterocycles, therefore the ethylization on 2 has high yield and highly-solid selectively, thereby, for example than having 2 diastereomers of going up " R " absolute configurations high more than 9 times or 9 times (80%d.e. or more than), obtain purpose formula [II] S type 2-substituted hydroxy-2-indoles mile pyridine base butyric ester compound with highly selective.Especially when the substituent R in compound [I] 0In substituting group " Y " when being 4-nitrophenyl alkylsulfonyl or 4-biphenyl sulfonyl, obtain described purpose compound to be respectively the much higher stereoselectivity that is higher than 20 times (90%d.e.) or 15.2 times (88%d.e.) and to be respectively 75% or 76% much higher separation yield.
The nitrogenous annelated heterocycles carboxylic acid cpd of formula of the present invention [IV] R type refers to compound with the carboxyl that connects nitrogenous annelated heterocycles (in this compound contained nitrogen-atoms protected); reach the carbon atom that connects described carboxyl and have " R " absolute configuration, described nitrogenous annelated heterocycles comprises benzo-fused nitrogen heterocyclic ring for example tetrahydroisoquinoline ring, tetrahydroquinoline ring, dihydroquinoline ring or indoline ring.
Suitable example with nitrogenous annelated heterocycles carboxylic acid cpd of " R " absolute configuration is formula [XIX] compound:
Figure A20061010119200181
Wherein, n is 0 or 1, and Y replaces or unsubstituted aryl sulfonyl or rudimentary alkyl sulphonyl.
Above n is that 1 compound [XIX] refers to N-and replaces-1,2,3, and 4-tetrahydrochysene-3-base quinoline carboxylic acid and n are that 0 compound [XIX] refers to N-and replaces 2-indoline carboxylic acid.Substituting group on the nitrogen-atoms of above-claimed cpd [XIX] " Y " comprises benzenesulfonyl; naphthalene sulfonyl base and biphenyl sulfonyl (they are optional by nitro, low alkyl group, lower alkoxy, cycloalkyl, halogen atom or thiophene phenyl replacement) or low alkyl group alkylsulfonyl be benzenesulfonyl, tosyl group, 2 for example; 4,6-Three methyl Benzene alkylsulfonyl, 4-oil of mirbane alkylsulfonyl, 4-chlorobenzene alkylsulfonyl, 4-anisole alkylsulfonyl, 4-phenylcyclohexane alkylsulfonyl, 4-(3-thiophene phenyl) benzenesulfonyl, 2-naphthyl alkylsulfonyl, 4-biphenyl sulfonyl, methyl sulphonyl and ethylsulfonyl.
In above-claimed cpd; preferred compound is that the substituting group " Y " on the wherein said nitrogen-atoms is tosyl group, 2-naphthyl alkylsulfonyl, 2; 4,6-Three methyl Benzene alkylsulfonyl, 4-biphenyl sulfonyl or 4-oil of mirbane alkylsulfonyl and n are that 1 compound [XIX] and the substituting group " Y " on the wherein said nitrogen-atoms are that tosyl group and n are 0 compounds [XIX].Particularly preferred compound is that the substituting group " Y " on the wherein said nitrogen-atoms is that 4-biphenyl sulfonyl or 4-oil of mirbane alkylsulfonyl and n are 1 compounds [XIX].
Described R 1And R 2Be low alkyl group for example methyl, ethyl, propyl group, sec.-propyl, normal-butyl, isobutyl-; X is for example chlorine, bromine, an iodine of halogen atom.E comprises any conventional ester residue, for example low alkyl group such as methyl, ethyl, propyl group, sec.-propyl, normal-butyl or isobutyl-.Wherein, preferred substituted is R 1And R 2Be methyl, X is chlorine atom or bromine atoms, and E is methyl or ethyl.
2-halo-2-indoles mile pyridine yl acetate compound [III] carries out with nitrogenous annelated heterocycles carboxylic acid cpd of R type [IV] or being reflected in the suitable solvent of its salt.
The salt of the nitrogenous annelated heterocycles carboxylic acid cpd of R type [IV] comprises an alkali metal salt (for example sylvite, sodium salt), alkaline earth salt (for example magnesium salts, calcium salt).
2-halo-2-indoles mile pyridine yl acetate compound [III] preferably carries out in the scavenging agent existence of acid or not with the reaction of the nitrogenous annelated heterocycles carboxylic acid cpd of R type [IV] or its salt.The suitable example of the scavenging agent of described acid comprises for example alkalimetal hydride (lithium hydride for example of mineral alkali, sodium hydride, potassium hydride KH), alkali metal ammonia compound (lithamide for example, ammonification sodium, ammonification potassium), alkaline carbonate (yellow soda ash for example, salt of wormwood), alkali metal hydrocarbonate (sodium bicarbonate for example, saleratus), alkali metal hydroxide (sodium hydroxide for example, potassium hydroxide, lithium hydroxide) and organic bases alkali metal alcoholates (sodium ethylate for example for example, potassium tert.-butoxide), basic metal alkyl amide (for example di-isopropyl lithamide), trialkylamine (triethylamine for example, (Trimethylamine 99), N, N-dialkyl aniline (N for example, accelerine), 1,8-diazabicylo [5.4.0] 11-7-alkene.
Used solvent comprises any described reaction not being had the conventional solvent of influence in described reaction, and suitable example is amide solvent (for example dimethyl formamide, N,N-DIMETHYLACETAMIDE), ether solvent (for example tetrahydrofuran (THF), dme, two  alkane).Described reaction is generally at 20-100 ℃, carries out under preferred 50-70 ℃.
The 2-of mile pyridine yl acetate compound [I] of 2-substituted hydroxy-2-indoles thereafter ethylizes in the presence of the scavenging agent of acid, carries out in suitable solvent.
Described ethylating agent is preferably halogen ethane (for example iodoethane, monobromethane), more preferably iodoethane.The scavenging agent of described acid is and the above-mentioned reacting phase reagent together that is used for 2-halo-2-indoles mile pyridine yl acetate compound [III] and the nitrogenous annelated heterocycles carboxylic acid cpd of R type [IV] or its salt that particularly preferred reagent is sodium hydride.
The solvent that is used for described reaction comprises any conventional solvent that described reaction is not had influence, suitable example is amide solvent (for example dimethyl formamide, N,N-DIMETHYLACETAMIDE), sulfoxide kind solvent (for example dimethyl sulfoxide (DMSO)), ether solvent (for example tetrahydrofuran (THF), two  alkane, dme), aromatic solvent (for example toluene, dimethylbenzene, benzene, chlorobenzene) or their mixture, and particularly preferred solvent is the mixture of N,N-DIMETHYLACETAMIDE and toluene.Described reaction is generally at-10-50 ℃, particularly preferably in carrying out under the room temperature.
Easily the purpose compound [II] with the crude product form that so obtains of recrystallization purifying produces highly purified compound [II].
Make the S type 2-substituted hydroxy-2-indoles mile pyridine base butyric ester compound [II] that so obtains through catalytic reduction; reduce its cyano group; make it through alkanoylization then; production [V] S type 2-substituted hydroxy-2-(6-replaces aminomethyl indoles mile pyridine base) butyric ester compound; and make this reaction product through nitrosation reaction and rearrangement; production [VI] S type 2-substituted hydroxy-2-(6-replaces skatoxyl mile pyridine base) butyric ester compound, its Chinese style [V] and [VI] are as follows:
Figure A20061010119200201
Wherein, R 3Be the lower alkane acyl group, other symbol as defined above,
Wherein symbol as defined above.Then, make compound [VI], thereafter or in cyclization, make its acetal radical change ketone group into, produce S type 4-type 4-substituted hydroxy-pyranindolelidinyl compounds [VII] through intramolecular cyclization reaction:
Figure A20061010119200211
Wherein symbol as defined above.
Above-claimed cpd [VII] and the adjacent anilid compound of formula [XIV] are reacted through Friedlaender in a usual manner, and production [XV] has the substituent Comptothecin compounds on 20 hydroxyls, makes described compound [XV] through removing R 0Base, and as described R 5-R 9When group is protected, also make it remove protecting group, optional in addition its salt that changes into, production [XVI] Comptothecin compounds or its salt, wherein said formula [XIV], [XV] and [XVI] are as follows:
Wherein, described R 5-R 9Group respectively is hydrogen atom or optional protected substituting group,
Figure A20061010119200213
Wherein symbol as defined above,
Figure A20061010119200221
Substituent R wherein 51-R 91Respectively be hydrogen atom or not protected substituting group.
In addition, suppose in the intramolecular cyclization reaction of above-mentioned S type 2-substituted hydroxy-2-(6-replaces skatoxyl mile pyridine base) butyric ester compound [VI], produce following formula: compound:
Figure A20061010119200222
Wherein symbol as defined above.
Also can prepare Comptothecin compounds [XVI] or its salt by the method that comprises the following step:
(a-1) make S type 4-type 4-substituted hydroxy-pyranindolelidinyl compounds [VII] remove R 0Group, or
(a-2) make S type 2-substituted hydroxy-2-(6-replaces skatoxyl mile pyridine base) butyric ester compound [VI] through the ester hydrolysis, production [IX] S type 2-hydroxyl-2-(6-skatoxyl mile pyridine base) butyric acid compound, compound [IX] is reached through intramolecular cyclization reaction change its acetal radical into ketone group simultaneously thereafter or with cyclization, also optionally change its product into its salt, production [VIII] S type 4-hydroxyl Pyranoindole mile acridine compound or its salt, wherein said formula [IX] and [VIII] are as follows:
Figure A20061010119200223
Wherein symbol as above defines,
(b) make compound [VIII] and adjacent anilid compound [XIV] react production [XVII] Comptothecin compounds in a usual manner through Friedlaender:
Figure A20061010119200232
Wherein symbol as defined above,
(c) make compound [XVII] remove R 5-R 9The protecting group of group (when these groups comprise protecting group) reaches
(d) optionally change this product into its salt.
In addition, can prepare Comptothecin compounds [XVI] or its salt by the method that comprises the following steps:
(i) make S type 2-substituted hydroxy-2-(6-replaces skatoxyl mile pyridine base) butyric ester compound [VI] produce S type 2-hydroxyl-2-(6-skatoxyl mile pyridine base) butyric acid compound [IX] or its salt through the ester hydrolysis,
(ii) make compound [IX] through intramolecular cyclization reaction and optionally change its product into its salt, production [X] S type 4-hydroxyl Pyranoindole mile acridine compound or its salt:
Figure A20061010119200233
Wherein symbol as defined above,
(iii) make the reaction of compound [X] and formula [XI] lower alkanols alkanoic acid or its derivatives reactivity, production [XII] S type 4-alkanoyloxy Pyranoindole mile acridine compound, its Chinese style [XI], [XII] are as follows: R 4OH[XI] wherein, R 4Be the lower alkane acyl group,
Wherein symbol as defined above,
(iv) make the acetal radical of described compound [XII] change ketone group into, production [XIII] S type 4-alkanoyloxy Pyranoindole mile acridine compound:
Figure A20061010119200242
Wherein symbol as defined above,
(above-claimed cpd [XIII] and adjacent anilid compound [XIV] are reacted through Friedlaender in a usual manner, and production [XVIII] has the substituent Comptothecin compounds on 20 hydroxyls:
Figure A20061010119200243
Wherein symbol as defined above,
(vi) make described compound [XVIII] remove R 4Group reaches also removes R 5-R 9The protecting group of group (when these groups comprise protecting group), and
(vii) optionally change this product into its salt.
In above-claimed cpd, substituent R 5-R 9Comprise that any and known camptothecin derivative is (for example referring to EP-A-540099, EP-A-296597, JP-A-6-228141, WO 90/03169, EP-A-418099) and No. the 757049th, european patent application with No. 781781 in identical substituting group in the disclosed camptothecin derivative, for example following substituting group:
(a) at described R 5-R 9In two adjacent substituting groups have the straight or branched alkylidene group of 2-6 carbon atom in conjunction with formation, or be hydrogen atom, and in all the other substituting groups one is-Q q-AlK p-R 10, other remaining two substituting groups are hydrogen atom, replacement or unsubstituted low alkyl group or halogen atom,
(b) at described R 5-R 9In two adjacent substituting groups have the straight or branched alkylidene group of 2-6 carbon atom in conjunction with formation, and any one carbon atom on described alkylidene group is replaced by the following formula group :-Q q-AlK p-R 10, R 5-R 9Three groups of residue be hydrogen atom, replacement or unsubstituted low alkyl group or halogen atom, at above-mentioned (a) with (b), one or two methylene radical in described alkylidene group can by-O-,-S-or-NH-replaces,
Q is-O-or-NH-,
AlK is the straight or branched alkylidene group with 1-6 carbon atom, and it is optional is inserted by Sauerstoffatom,
R 10Be protected amino, protected low-grade alkyl amino, protected Piperazino (piperazino) or protected hydroxyl,
P and q are 0 or 1, or when p was 1, q was 0.
Described R 51-R 91Be by R 5-R 9Remove deutero-group after the protecting group, particularly with regard to R 5-R 9Defined group, wherein radicals R 10For by removing the group that protecting group obtains, i.e. R 10Be amino, low alkyl group amido, Piperazino or hydroxyl.
Preferred R 51-R 91The combination of group is as follows:
(i) R 71Be the amino propoxy-of 3-, R 51Be ethyl, and R 61, R 81And R 91Respectively be hydrogen atom,
(ii) R 51Be the Piperazino methyl, R 61And R 91Respectively be hydrogen atom, and R 71And R 81In conjunction with the formation ethylenedioxy,
(iii) R 51Be aminomethyl, R 71And R 81In conjunction with forming ethylenedioxy, reach R 61And R 91Respectively be hydrogen atom,
(iv) R 51Be aminomethyl, R 71And R 81In conjunction with forming methylene-dioxy, reach R 61And R 91Respectively be hydrogen atom,
(v) R 61Be amino, and R 51, R 71, R 81And R 91Respectively be hydrogen atom,
(vi) R 51And R 61In conjunction with forming the amino trimethylene that replaces, R 71Be methyl, R 81Be fluorine atom and R 91Be hydrogen atom,
(vii) R 51And R 61In conjunction with forming trimethylene, R 71Be 3-aminopropyl oxygen base, R 81And R 91Respectively be hydrogen atom,
(viii) R 71Be 3-aminopropyl oxygen base, and R 51, R 61, R 81And R 91It respectively is hydrogen atom.
The salt of S type 4-hydroxyl Pyranoindole mile acridine compound [VIII], S type 2-hydroxyl-2-(6-skatoxyl mile pyridine base) butyric acid compound [IX] or S type 4-hydroxyl Pyranoindole mile acridine compound [X] comprise the salt of an alkali metal salt (for example sodium salt, lithium salts) and Comptothecin compounds [XVI] comprise with the salt (for example hydrochloride, vitriol) of mineral acid or with organic acid salt (for example oxalate, tosylate).
In the above-mentioned method for preparing Comptothecin compounds, the reduction and the alkanoyl process of S type 2-substituted hydroxy-2-indoles mile pyridine base butyric ester compound [II] are carried out in suitable solvent.Catalyzer (for example Raney nickel) is generally used in described reduction, in hydrogen, carries out under room temperature to 60 ℃.Described alkanoylization is generally used conventional alkane acylating agent (for example lower alkanols alkanoic acid, lower alkane carboxylic acid halides, lower alkane acid anhydrides), carries out under room temperature to 60 ℃.Solvent for use comprises lower alkane acid anhydrides (for example diacetyl oxide), lower alkanols alkanoic acid (for example acetate) or their mixture in these reactions.When lower alkane acid anhydrides, lower alkanols alkanoic acid or their mixture were used for described reduction reaction, they also can be used as the alkanoyl agent, and in this case, described reduction and alkanoylization can be carried out in a step.
The nitrosification of S type 2-substituted hydroxy-2-(6-replaces aminomethyl indoles mile pyridine base) butyric ester compound [V] and rearrangement can be by being similar to (23 volumes at Journal of Medicinal Chemistry, the 554-560 page or leaf, 1980) go up disclosed method, in suitable solvent, carry out.Conventional nitrosation agent (for example Sodium Nitrite, potassium nitrite) is used in described nitrosification, under acidic conditions, carries out in 0 ℃.The used solvent of this reaction comprises lower alkane acid anhydrides (for example diacetyl oxide), lower alkanols alkanoic acid (for example acetate) or their mixture.
Described rearrangement reaction thereafter can be undertaken by the product that the above-mentioned nitrosification process of heating under 60-70 ℃ obtains.Used solvent comprises halocarbon (for example tetracol phenixin, chloroform, methylene dichloride), ester solvent (for example ethyl acetate), non-aromatics solvent (for example normal hexane), aromatic solvent (for example toluene) in rearrangement reaction.
The ester hydrolysis of S type 2-substituted hydroxy-2-(6-replaces skatoxyl mile pyridine base) butyric ester compound [VI] can in the presence of alkali, be carried out in suitable solvent by being used for esterolytic ordinary method.
Used alkali comprises mineral alkali for example alkali metal hydroxide (lithium hydroxide, sodium hydroxide, potassium hydroxide), alkaline earth metal hydroxides (for example calcium hydroxide), ammonium hydroxide, alkaline carbonate (for example yellow soda ash, salt of wormwood), alkali metal hydrocarbonate (for example sodium bicarbonate) in the ester hydrolysis, organic bases for example alkali metal alcoholates (for example sodium ethylate, sodium methylate), alkali metal phenolate (for example phenol sodium), one-level-, secondary-or three grades-rudimentary alkanamine (for example methylamine, ethamine, N, N-dimethyl-1,3-propylene diamine, Trimethylamine 99, triethylamine).Described solvent comprises the mixture of alcoholic solvent (for example methyl alcohol, ethanol, propyl alcohol, Virahol, butanols), sulfoxide solvent (for example methyl-sulphoxide), halogenated hydrocarbon solvent (for example methylene dichloride), ether solvents (for example tetrahydrofuran (THF)) or described organic solvent and water.When described alkali was liquid, it also can be used as solvent.Described reaction is preferable over 0-50 ℃, more preferably carries out under room temperature.
When the intramolecular cyclization reaction of S type 2-substituted hydroxy-2-(6-replace skatoxyl mile pyridine base) butyric ester compound [VI] or S type 2-hydroxyl-2-(6-skatoxyl mile pyridine base) butyric acid compound [IX] or its salt and acetal radical thereof changed ketone group into and carry out simultaneously, they can be undertaken by going on foot with this compound one of suitable acid treatment.Described acid comprises the mixture of mineral acid (for example hydrochloric acid, sulfuric acid), organic acid (for example trifluoroacetic acid) and they and water.This acid also can be used as solvent.
On the other hand, when the intramolecular cyclization reaction of S type 2-substituted hydroxy-2-(6-replace skatoxyl mile pyridine base) butyric ester compound [VI] or S type 2-hydroxyl-2-(6-skatoxyl mile pyridine base) butyric acid compound [IX] or its salt at first carries out, carry out its acetal radical then when changing the process of ketone group into, described reaction can be handled this compound by the acid (for example acetate, citric acid) that use is weaker than the used acid of above-mentioned single step reaction, uses then with the mode of its reaction product of acid treatment of the used same intensity of above-mentioned single step reaction and carries out.For example, when with more weak acid treatment S type 2-hydroxyl-2-(6-skatoxyl mile pyridine base) butyric acid compound [IX] or its salt, obtain S type 4-hydroxyl Pyranoindole mile acridine compound [X], by with stronger acid treatment it, make it change S type 4-hydroxyl Pyranoindole mile acridine compound [VIII] into.
The reaction of S type 4-hydroxyl Pyranoindole mile acridine compound [X] or its salt and lower alkanols alkanoic acid [XI] or its derivatives reactivity can be carried out in the presence of alkali.
Described lower alkanols alkanoic acid [XI] comprises for example acetate, and its derivatives reactivity comprises acid anhydrides (for example diacetyl oxide), carboxylic acid halides (for example Acetyl Chloride 98Min.), active ester (for example p-nitrophenyl ester).Described alkali comprises alkalimetal hydride (for example sodium hydride, potassium hydride KH), alkaline carbonate (for example yellow soda ash, salt of wormwood), alkali metal hydrocarbonate (for example sodium bicarbonate, saleratus), pyridine and 4-N, N-dimethyl aminopyridine.Described reaction is preferable under the room temperature and carries out generally in 0-50 ℃.
Thereafter the process that the acetal radical of S type 4-type 4-substituted hydroxy-pyranindolelidinyl compounds [XII] is changed into ketone group can be by carrying out with this compound of suitable acid treatment.Described acid can be to change the used identical acid of ketone group into intramolecular cyclization reaction and the acetal radical thereof of finishing S type 2-substituted hydroxy-2-(6-replaces skatoxyl mile pyridine base) butyric ester compound [VI] or S type 2-hydroxyl-2-(6-skatoxyl mile pyridine base) butyric acid compound [IX] or its salt with a step.
S type 4-type 4-substituted hydroxy-pyranindolelidinyl compounds [VII], S type 4-hydroxyl Pyranoindole mile acridine compound [VIII] or its salt or S type 4-type 4-substituted hydroxy-pyranindolelidinyl compounds [XIII] can be according to known Friedlaender reaction [referring to Organic Reactions with the reaction of adjacent anilid compound [XIV], 28 volumes, the 37-202 page or leaf, John Wiley ﹠amp; Sons, Inc., NewYork (1982)] carry out.
Described 4-type 4-substituted hydroxy-pyranindolelidinyl compounds [VII] and 4-alkanoyloxy Pyranoindole mile acridine compound [XIII] are more stable and in the Friedlaender reaction than S type 4-hydroxyl Pyranoindole mile acridine compound [VIII] or its salt; decomposition influence to adjacent anilid compound [XIV] is less; therefore can reduce unwanted impurity by product; thereby; described compound can be advantageously used in the described reaction with more a spot of adjacent anilid compound [XIV], and for example purifying can be with higher yield generation purpose Comptothecin compounds [XVI] to comprise simple post-reaction treatment process.
In addition, 4-alkanoyloxy Pyranoindole mile acridine compound [XIII] has much smaller than the molecular weight of 4-type 4-substituted hydroxy-pyranindolelidinyl compounds [VII], therefore, it can be used in the Friedlaender reaction with less amount (needing less reaction vessel).
Remove R 5-R 9The process of contained protecting group can be undertaken by being suitable for wherein the ordinary method of contained protecting group in the group.For example; when described amino protecting group is benzyloxycarbonyl; can be by in suitable solvent (for example tetrahydrofuran (THF), methyl alcohol); catalytic reduction in the presence of palladium-carbon is removed; and when described amino protecting group is tert-butoxycarbonyl; can handle it with acid (for example hydrochloric acid, trifluoroacetic acid) by in suitable solvent (for example tetrahydrofuran (THF), methyl alcohol, two  alkane, methylene dichloride), be removed.
Remove R by S type 4-type 4-substituted hydroxy-pyranindolelidinyl compounds [VII] or by the Comptothecin compounds with 20-substituted hydroxy [XV] 0The process of residue can be by in suitable solvent, and the conventional ester hydrolysis in the presence of alkali is finished.Alkali that the ester hydrolytic process of described alkali and solvent and S type 2-substituted hydroxy-2-(6-replaces skatoxyl mile pyridine base) butyric ester compound [VI] is used and solvent phase are together.Described reaction can be carried out under cooling, room temperature or heating condition.
In addition, by removing radicals R in the Comptothecin compounds with 20-alkanoyl hydroxyl [XVIII] 4Process can remove R with the ester hydrolysis of S type 2-substituted hydroxy-2-(6-replace skatoxyl mile pyridine base) butyric ester compound [VI] or by S type 4-type 4-substituted hydroxy-pyranindolelidinyl compounds [VII] or by the Comptothecin compounds with 20-substituted hydroxy [XV] 0The used same procedure of residue process is carried out.
Can prepare the adjacent anilid compound [XIV] that is used for above-mentioned condensation reaction by method shown in the following reaction scheme-1:
Reaction scheme-1
Figure A20061010119200301
Wherein symbol as defined above.
Promptly use oxygenant (for example activated manganese dioxide, dichromic acid pyridine ) to handle oxy-compound [XXII]; produce ketone compound [XXIII]; then in suitable solvent; in the presence of appropriate catalyst (for example palladium-carbon); make it through catalytic reduction, produce the adjacent anilid compound [XIV] of purpose.In addition, when removing R by catalytic reduction 5-R 9In protecting group the time, can make described product introduce protecting group again, produce adjacent anilid compound [XIV].In addition, by with oxidizer treatment R wherein 5Be the oxy-compound [XXII] of low-grade alkenyl, also can prepare wherein R by catalytic reduction then 5It is the adjacent anilid compound [XIV] of low alkyl group.
In addition, protecting group is introduced on the corresponding compound with protecting group not, also can be prepared wherein R by ordinary method 5-R 9Group has the oxy-compound [XXII] of the hydroxyl of the Piperazino of low-grade alkyl amino, protection of amino, the protection of protection or protection.
2-halo-2-indoles mile pyridine yl acetate the compound [III] that is used for the present invention also can prepare by method shown in the following reaction scheme-2 for new compound.
Reaction scheme-2
Figure A20061010119200311
Wherein symbol as defined above.
Even indoles mile acridine compound [XXIV] is in the presence of acid (for example tosic acid) or Lewis acid (for example trimethylsilyl chloride) and 1, ammediol compound [XXV] reaction, produce indoles mile pyridine methylmethane compound [XXVI], and at suitable solvent (toluene for example, tetrahydrofuran (THF)) in, at alkali (sodium hydride for example, potassium tert.-butoxide) exists down, handle described compound [XXVI] with carboxylic acid diesters [XXVII], produce 2-indoles mile pyridine yl acetate compound [XXVIII], make its further halogenation by ordinary method, produce purpose 2-halo-2-indoles mile pyridine yl acetate compound [III].
In the nitrogenous annelated heterocycles carboxylic acid cpd of R type [IV] or its salt, nitrogenous annelated heterocycles carboxylic acid cpd [XIX] or its salt are new compound and can replace nitrogenous annelated heterocycles carboxylic acid cpd or its salt and formula [XXX] sulfonic acid or its derivatives reactivity or its salt by conventional sulphonamide formation prepared in reaction by making formula [XXIX] N-, for example by making the prepared in reaction of halogenide (for example muriate) in the presence of alkali (for example alkali metal hydroxide) of nitrogenous annelated heterocycles carboxylic acid cpd [XXIX] and sulfonic acid [XXX], wherein said formula [XXIX] and [XXX] are as follows:
Figure A20061010119200312
Wherein symbol as defined above,
YOH [XXX]
Wherein symbol as defined above.
In this specification sheets and claims; term " S type " refers to 2-substituted hydroxy-2-indoles mile pyridine base butyric ester compound [II]; 2-substituted hydroxy-2-(6-replaces aminomethyl indoles mile pyridine base) butyric ester compound [V]; absolute configuration or 4-type 4-substituted hydroxy-pyranindolelidinyl compounds [VII] on 2 of 2-substituted hydroxy-2-(6-replaces skatoxyl mile pyridine base) butyric ester compound [VI] or 2-hydroxyl-2-(6-skatoxyl mile pyridine base) butyric acid compound [IX] or its salt; 4-hydroxyl Pyranoindole mile acridine compound [VIII] or its salt; 4-hydroxyl Pyranoindole mile acridine compound [X] or its salt; absolute configuration on 4 of 4-alkanoyloxy Pyranoindole mile acridine compound [XII] or 4-alkanoyloxy Pyranoindole mile acridine compound [XIII], and 2-[(R)-N-tosyl group prolyl oxygen base]-absolute configuration on 2 of 2-indoles mile pyridine base butyric ester compound [XXI] is " S " configuration.
In this specification sheets and claims full text; term " low alkyl group " refers to the straight or branched alkyl with 1-6 carbon atom, and term " lower alkane acyl group " and " lower alkanols alkanoic acid " refer to the alkanoyl and the paraffinic acid of the straight or branched that has 1-7 carbon atom respectively.Term " alkylidene group " refers to the straight or branched alkylidene group with 1-10 carbon atom.
Embodiment
Explain the present invention more accurately by the following example with reference to embodiment, but do not think limitation ot it.
Embodiment 1
(1) with 2-bromo-2-[6-cyano group-1; 1-(2; 2-dimethyl-1; the inferior third dioxy base of 3-)-and 5-oxygen-1,2,3; 5-tetrahydrochysene-7-indoles mile pyridine base] ethyl acetate (22.21g), (3R)-N-(4-biphenyl sulfonyl)-1; 2,3,4-tetrahydrochysene-3-1-isoquinolinecarboxylic acid (24.70g) and the mixture of salt of wormwood (5.11g) in dimethyl formamide (220ml) stirred 70 minutes down in 60 ℃.With this reaction mixture of ethyl acetate extraction, and wash this extracting solution with saturated brine solution, and through dried over sodium sulfate.After removing solvent under reduced pressure; its resistates purification by silica gel column chromatography (elutriant: chloroform: ethyl acetate=10: 1 → 6: 1), produce the 2-[[(3R of colourless powder shape)-N-(4-biphenyl sulfonyl-)-1,2; 3; 4-tetrahydrochysene-3-isoquinolyl] the ketonic oxygen base]-2-[6-cyano group-1, and 1-(2,2-dimethyl-1; the inferior third dioxy base of 3-)-5-oxygen-1; 2,3,5-tetrahydrochysene-7-indoles mile pyridine base] ethyl acetate (35.41g).
Yield: 92%
IR (Nujol, cm -1): 2220,1750,1665,1615 (Nujol: whiteruss)
MS(m/z):738(MH +)
NMR(300MHz,CDCl 3,δ):0.89?and?0.90(3H,s),1.10?and?1.15(3H,t,J=7Hz),1.33?and?1.35(3H,s),2.45-2.60(2H,m),3.25-3.40(2H,m),3.61-3.76(4H,m),3.95-4.22(4H,m),4.58?and?4.68(1H,d,J=16Hz),4.72?and?4.75(1H,d,J=16Hz),5.22?and?5.29(1H,dd?and?t,J=3.6?and?5Hz),6.01?and?6.04(1H,s),6.58?and6.65(1H,s),7.02-7.20(4H,m),7.37-7.51(3H,m),7.54-7.60(2H,m),7.62-7.68(2H,m),7.85-7.93(2H,m)
(2) with 2-[[(3R)-N-(4-biphenyl sulfonyl-)-1,2,3; 4-tetrahydrochysene-3-isoquinolyl] the ketonic oxygen base]-2-[6-cyano group-1; 1-(2,2-dimethyl-trimethylenedioxy)-5-oxygen-1; 2; 3,5-tetrahydrochysene-7-indoles mile pyridine base] ethyl acetate (33.63g) be dissolved in exsiccant N,N-DIMETHYLACETAMIDE-toluene (1: 1) (330ml) in, add 60% oily dispersion of sodium hydride (2.21g) (1.2 equivalent); and under room temperature, stirred this mixture 75 minutes.Iodoethane (36.5ml) (10 equivalent) is added in this mixture, and under room temperature, it spends the night restir.With this reaction mixture of ethyl acetate extraction, and wash described extracting solution,, use activated carbon (5g) to handle then through sodium sulfate-dried over mgso with lemon aqueous acid and saturated brine liquid.After removing solvent under reduced pressure, with its residue (35.69g) [cis-selectivity of 2S compound and 2R compound=15.2: 1.0 (88%d.e.), it is according to δ in the NMR spectrum: the ratio of the integrated value at 6.71 and 6.46 peaks calculates and gets] be dissolved in the acetone (60ml), and under room temperature, stir this mixture, and add hexane (76ml) in batches, also add the kind crystalline substance of purpose diastereomer.Filter the crystallization that collecting precipitation goes out; (about 100ml) washes with acetone-hexane (60: 76), produces (2S)-the 2-[[(3R)-N-(4-biphenyl sulfonyl-)-1,2 of colourless crystallization shape; 3; 4-tetrahydrochysene-3-isoquinolyl] the ketonic oxygen base]-2-[6-cyano group-1, and 1-(2,2-dimethyl-1; the inferior third dioxy base of 3-)-5-oxygen-1; 2,3,5-tetrahydrochysene-7-indoles mile pyridine base] ethyl butyrate (26.64g).
Yield: 76%
Figure A20061010119200341
M.p.:>82 ℃ (decomposing gradually)
[α] D 26:-43.3 ° (c=1.02, chloroform)
IR(Nujol;cm -1):2220,1755,1660,1615
MS(m/z):766(MH +)
NMR(300MHz,CDCl 3,δ):0.70(3H,t,J=7.5Hz),0.85(3H,brs),1.02(3H,t,J=7Hz),1.21(3H,brs),2.16-2.55(4H,m),3.35(1H,dd,J=6.5?and?16Hz),3.50(1H,dd,J=3?and?16Hz),3.55-3.70(4H,m),3.70-3.90(2H,m),3.93-4.16(2H,m),4.68(1H,d,J=16Hz),4.76(1H,d,J=16Hz),5.37(1H,dd,J=3?and?6.5Hz),6.71(1H,s),7.02-7.10(1H,m),7.10-7.20(3H,m),7.36-7.50(3H,m),7.54-7.59(2H,m),7.63-7.68(2H,m),7.89-7.96(2H,m)
(3) with (2S)-2-[[(3R)-N-(4-biphenyl sulfonyl-)-1,2,3,4-tetrahydrochysene-3-isoquinolyl]
The ketonic oxygen base]-2-[6-cyano group-1,1-(2,2-dimethyl-1, the inferior third dioxy base of 3-)-and 5-oxygen-1,2,3,5-tetrahydrochysene-7-indoles mile pyridine base] ethyl butyrate (23.71g) and Raney nickel (W-4) (49g) is dissolved in diacetyl oxide-acetate (460ml: 190ml), in hydrogen, under 50-60 ℃, stir this mixture.After reaction is finished; leach catalyzer; and under reduced pressure concentrated its filtrate; make its residue through purification by silica gel column chromatography (elutriant: chloroform: methyl alcohol=100: 1 → 70: 1 → 60: 1); produce (2S)-the 2-[[(3R)-N-(4-biphenyl sulfonyl-)-1 of yellow powder powder; 2; 3; 4-tetrahydrochysene-3-isoquinolyl] the ketonic oxygen base]-the 2-[6-[(kharophen) methyl]-1,1-(2,2-dimethyl-1; the inferior third dioxy base of 3-)-5-oxygen-1; 2,3,5-tetrahydrochysene-7-indoles mile pyridine base] ethyl butyrate (22.10g).
Yield: 87%
Figure A20061010119200351
[α] D 26:-14.9 ° (c=1.01, chloroform)
IR(Nujol,cm -1):3405,3295,1750,1660
MS(m/z):812(MH +)
NMR(300MHz,CDCl 3,δ):0.69(3H,t,J=7.5Hz),0.88(3H,s),1.02(3H,t,J=7Hz),1.24(3H,s),1.96(3H,s),2.12-2.55(4H,m),3.31(1H,dd,J=6.5?and16Hz),3.41(1H,dd,J=3?and?16Hz),3.59(2H,s),3.63(2H,s),3.84(1H,dq,J=11and?7Hz),3.94-4.14(3H,m),4.54(1H,dd,J=14?and?5.5Hz),4.58-4.68(1H,m),4.63(1H,d,J=15Hz),4.71(1H,d,J=15Hz),5.25(1H,dd,J=3?and?6.5Hz),6.74(1H,s),7.00-7.19(5H,m),7.37-7.50(3H,m),7.54-7.64(4H,m),7.83-7.89(2H,m)
(4) with (2S)-2-[[(3R)-N-(4-biphenyl sulfonyl-)-1,2,3; 4-tetrahydrochysene-3-isoquinolyl] the ketonic oxygen base]-the 2-[6-[(kharophen) methyl]-1; 1-(2,2-dimethyl-trimethylenedioxy)-5-oxygen-1; 2; 3,5-tetrahydrochysene-7-indoles mile pyridine base] ethyl butyrate (30.16g) be dissolved in diacetyl oxide-acetate (450ml: 150ml), ice-cooled down; add Sodium Nitrite (13.18g), on ice-water bath, stirred this mixture 4 hours.This reaction mixture is poured in the chloroform (1.5 liters), and the material separated is not allowed in elimination.Under reduced pressure, its filtrate is evaporated to dried, its residue is mixed with ethyl acetate (900ml), stirred these mixtures 13 hours down in 60 ℃.(700ml) dilutes this reaction mixture with ethyl acetate, reaches water and salt and washes this mixture, through dried over sodium sulfate, then, uses activated carbon treatment.After removal of solvent under reduced pressure; make the crystallization from ethyl acetate-hexane of its resistates, produce colourless rib crystalline (2S)-2-[[(3R)-N-(4-biphenyl sulfonyl-)-1,2; 3; 4-tetrahydrochysene-3-isoquinolyl] the ketonic oxygen base]-2-[6-acetyl-o-methyl-1, and 1-(2,2-dimethyl-1; the inferior third dioxy base of 3-)-5-oxygen-1; 2,3,5-tetrahydrochysene-7-indoles mile pyridine base] ethyl butyrate (16.77g).
Yield: 55%
Figure A20061010119200361
m.p.:145-148℃
[α] D 27:-9.6 ° (c=1.0, chloroform)
IR(Nujol,cm -1):1755,1659,1614
MS(m/z):813(MH +)
NMR(300MHz,CDCl 3,δ):0.54(3H,t,J=7.4Hz),0.88(3H,s),1.08(3H,t,J=7.1Hz),1.30(3H,s),2.09(3H,s),2.24(2H,q?like,J=7.6Hz),2.47(2H,t,J=7Hz),3.27(2H,m),3.65(4H,m),3.91-4.17(4H,m),4.64(1H,d,J=15.6Hz),4.72(1H,d,J=15.6Hz),5.13(1H,dd,J=5.3?and?3Hz),5.25(2H,s),6.65(1H,s),7.01-7.20(4H,m),7.37-7.50(3H,m),7.55-7.59(2H,m),7.65(2H,d?like,J=8.6Hz),7.90(2H,d?like,J=8.6Hz)
(5) with (2S)-2-[[(3R)-N-(4-biphenyl sulfonyl-)-1; 2; 3,4-tetrahydrochysene-3-isoquinolyl] the ketonic oxygen base]-2-[6-acetyl-o-methyl-1,1-(2; 2-dimethyl-1; the inferior third dioxy base of 3-)-and 5-oxygen-1,2,3; 5-tetrahydrochysene-7-indoles mile pyridine base] ethyl butyrate (1.457g) is dissolved in down in 80% the trifluoroacetic acid aqueous solution (15ml) ice-cooled, stirs this mixture 2 days under room temperature.Under reduced pressure concentrate this reaction mixture, with its resistates of chloroform extraction and wash with water, through dried over mgso.Under reduced pressure; evaporating this extracting solution desolvates to remove; produce (4S)-7 of colourless foam shape; 8-dihydro-4-ethyl-4-[[(3R)-N-(4-biphenyl sulfonyl-)-1,2,3; 4-tetrahydrochysene-3-isoquinolyl] the ketonic oxygen base]-1H-pyrans also [3; 4-f] indoles mile pyridine-3,6,10 (4H)-triketones (1.145g).
Yield: 100%
Figure A20061010119200371
IR(Nujol,cm -1):1746,1661
MS(m/z):639(MH +)
NMR(300MHz,CDCl 3,δ):0.82(3H,t,J=7.5Hz),1.78-2.09(4H,m),2.66-2.90(2H,m),3.23(2H,d?like,J=4.6Hz),4.07-4.27(2H,m),4.53(1H,d,J=15.4Hz),4.69(1H,d,J=15.6Hz),5.01(1H,t,J=5.2Hz),5.23(1H,d,J=18Hz),5.49(1H,d,J=17.9Hz),6.58(1H,s),7.01-7.18(4H,m),7.38-7.56(5H,m),7.62(2H,dlike,J=8.6Hz),7.89(2H,d?like,J=8.6Hz)
(6) with (4S)-7; 8-dihydro-4-ethyl-4-[[(3R)-N-(4-biphenyl sulfonyl-)-1; 2; 3,4-tetrahydrochysene-3-isoquinolyl] the ketonic oxygen base]-also [3,4-f] the indoles mile pyridine-3 of 1H-pyrans; 6; 10 (4H)-triketones (1.145g) and 1-[5 '-(3 "-(tert-butoxycarbonyl amino propoxy-)-2 '-aminophenyl] third-1-ketone (867mg) is dissolved in the acetate (15ml), under 60 ℃, stirs this mixture 47 hours.Under reduced pressure; concentrate this reaction mixture; the crude product that is produced purification by silica gel column chromatography (elutriant: chloroform: ethyl acetate=2: 1 → 1: 1); then; from ethyl acetate-hexane recrystallization, produce (20S)-7-ethyl-10-[3-(t-butoxycarbonyl amino) propoxy-of colourless crystallization shape]-20-O-[[(3R)-N-(4-biphenyl sulfonyl)-1,2; 3,4-tetrahydrochysene-3-isoquinolyl] carbonyl] camptothecine (1.11g).
Yield: 67%
Figure A20061010119200381
m.p.:213-216℃
IR(Nujol,cm -1):3407,1763,1753,1709,1669,1614
MS(m/z):925(MH +)
NMR(300MHz,CDCl 3,δ):0.86(3H,t,J=7.5Hz),1.35(3H,t,J=7.6Hz),1.46(9H,s),1.88-2.18(4H,m),2.94-3.20(2H,m),3.34(2H,d,J=4.8Hz),3.42(2H,q?like,J=6.4Hz),4.22(2H,t,J=6Hz),4.57(1H,d,J=15.4Hz),4.73-4.81(1H,br),4.81(1H,d,J=15.4Hz),4.90(1H,d,J=18.7Hz),5.09(1H,d,J=18.7Hz),5.21(1H,d,J=4.8Hz),5.26(1H,d,J=17.2Hz),5.51(1H,d,J=17.2Hz),6.99(1H,s),7.01-7.18(4H,m),7.22-7.29(2H,m),7.30-7.42(6H,m),7.49(1H,dd,J=9.3?and?2.7Hz),7.89(2H,d?like,J=8.6Hz),8.20(1H,d,J=9.2Hz)
(7) with (20S)-7-ethyl-10-[3-(t-butoxycarbonyl amino) propoxy-]-20-O-[[(3R)-N-(4-biphenyl sulfonyl)-1; 2; 3; 4-tetrahydrochysene-3-isoquinolyl] carbonyl] camptothecine (991mg) be dissolved in water-methanol (6ml: 30ml), ice-cooled down, add lithium hydroxide monohydrate (180mg); under room temperature; stirred this mixture 22 hours, under 50 ℃, restir 4 hours.Under reduced pressure, concentrate this reaction mixture, add chloroform (20ml) and acetate (4ml), under room temperature, stirred this mixture 19 hours.Dilute this reaction mixture with chloroform and water, reach water and saturated brine solution and wash its chloroform layer, through dried over sodium sulfate.Decompression is steamed down and is desolventized, and produces (20S)-7-ethyl-10-[3-(t-butoxycarbonyl amino) propoxy-] camptothecine.
Figure A20061010119200391
(8) with resulting (20S)-7-ethyl-10-[3-(t-butoxycarbonyl amino) propoxy-] camptothecine is dissolved in water-ethanol (5ml: 15ml), and add 6.6N hydrochloric acid-ethanol (5ml), under room temperature, stirred this mixture 23 hours.Under reduced pressure, evaporating this reaction mixture to dry doubling is dissolved in its resistates in ethyl acetate and the water.Water further extracts its ethyl acetate layer, merges its water layer and vapourisation under reduced pressure to doing.The crystallization from Virahol-water of its resistates produces light yellow pin crystalline (20S)-7-ethyl-10-(the amino propoxy-of 3-) camptothecine hydrochloride (240mg).
Yield: the total recovery of above (7) and (8) is 44%
Figure A20061010119200401
M.p.:>218 ℃ (decomposition)
[α] D 25:+9.8 ° (c=1.0, water)
MS(m/z):450(M-Cl +)
IR(Nujol,cm -1):3450,3370,1745,1660
NMR(300MHz,DMSO-d 6,δ):0.88(3H,t,J=7Hz),1.32(3H,t,J=8Hz),1.78-1.95(2H,m),2.08-2.19(2H,m),3.0-3.1(2H,m),3.13-3.25(2H,m),4.32(2H,t,J=6Hz),5.32(2H,s),5.43(2H,s),7.28(1H,s),7.50-7.56(2H,m),7.99(3H,brs),8.11(1H,d,J=10Hz)
Embodiment 2
(1) handle (4S)-7 that in embodiment 1-(5), obtain according to same procedure described in the embodiment 1-(7), 8-dihydro-4-ethyl-4-[[(3R)-N-(4-biphenyl sulfonyl-)-1,2; 3; 4-tetrahydrochysene-3-isoquinolyl] the ketonic oxygen base]-also [3,4-f] the indoles mile pyridine-3,6 of 1H-pyrans; 10 (4H)-triketones; produce (4S)-7,8-dihydro-4-ethyl-4-hydroxyl-1H-pyrans is [3,4-f] indoles mile pyridine-3 also; 6,10 (4H)-triketones.
Figure A20061010119200402
(2) according to embodiment 1-(6) and-same procedure described in (8) handles (4S)-7,8-dihydro-4-ethyl-4-hydroxyl-1H-pyrans is [3,4-f] indoles mile pyridine-3,6 also, 10 (4H)-triketones, (20S)-7-ethyl-10-of generation yellow powder shape (the amino propoxy-of 3-) camptothecine hydrochloride.
Figure A20061010119200411
Embodiment 3
(1) with 2-bromo-2-[6-cyano group-1; 1-(2; 2-dimethyl-trimethylenedioxy)-5-oxygen-1,2; 3; 5-tetrahydrochysene-7-indoles mile pyridine base] ethyl acetate (1.28g), (3R)-N-(4-nitrophenyl alkylsulfonyl)-1,2,3; 4-tetrahydrochysene-3-1-isoquinolinecarboxylic acid (1.63g) and salt of wormwood (357mg) mix in dimethyl formamide (15ml), and stir this mixture 20 minutes down in 70 ℃.Handle this reaction mixture according to the same procedure described in the embodiment 1-(1); produce the 2-[[(3R of colourless powder shape)-N-(4-nitrophenyl alkylsulfonyl)-1; 2,3,4-tetrahydrochysene-3-isoquinolyl] the ketonic oxygen base]-2-[6-cyano group-1; 1-(2; 2-dimethyl-trimethylenedioxy)-5-oxygen-1,2; 3,5-tetrahydrochysene-7-indoles mile pyridine base] ethyl acetate (2.10g).
Yield: 99%
IR(Nujol,cm -1):2225,1750,1665,1615
MS(m/z):707(MH +)
NMR(300MHz,CDCl 3,δ):0.89?and?0.90(3H,s),1.10?and?1.20(3H,t,J=7Hz),1.33?and?1.36(3H,s),2.54-2.63(2H,m),3.30-3.42(2H,m),3.60-3.75(4H,m),4.00-4.22(4H,m),4.50?and?4.57(1H,d,J=15Hz),4.78?and?4.83(1H,d,J=15Hz),5.22?and?5.32(1H,dd,J=3?and?6Hz),5.90?and?5.95(1H,s),6.48?and?6.54(1H,s),7.00-7.23(4H,m),8.01?and?8.05(2H,d,J=9Hz),8.29?and?8.31(2H,d,J=9Hz)
(2) with 2-[[(3R)-N-(4-nitrophenyl alkylsulfonyl)-1; 2; 3; 4-tetrahydrochysene-3-isoquinolyl] the ketonic oxygen base]-2-[6-cyano group-1; 1-(2; 2-dimethyl-1; the inferior third dioxy base of 3-)-5-oxygen-1; 2,3,5-tetrahydrochysene-7-indoles mile pyridine base] ethyl acetate (25.09g) be dissolved in exsiccant N,N-DIMETHYLACETAMIDE-toluene (1: 1) (240ml) in; according to the same procedure described in the embodiment 1-(2); 60% oily dispersion and iodoethane (54.58g) (10 equivalent) with sodium hydride (1680mg) (1.2 equivalent) make this mixture reaction, wash its extracting solution with aqueous citric acid solution and saturated brine solution, through dried over mgso.After removing solvent under reduced pressure; its resistates forms powder from ethyl acetate-ether, produce the 2-[[(3R of colourless powder shape)-N-(4-nitrophenyl alkylsulfonyl-)-1,2; 3; 4-tetrahydrochysene-3-isoquinolyl] the ketonic oxygen base]-2-[6-cyano group-1, and 1-(2,2-dimethyl-1; the inferior third dioxy base of 3-)-5-oxygen-1; 2,3,5-tetrahydrochysene-7-indoles mile pyridine base] ethyl butyrate (mixture of diastereomer) is (22.04g).The cis-selectivity of 2S compound and 2R compound=20.0: 1.0 (90%d.e.), it is according to δ in the NMR spectrum: the ratio of the integrated value at 6.85 and 6.41 peaks calculates and gets.Make this colourless powder recrystallization from Virahol, produce the pure product (19.32g) of colourless crystallization shape.
Yield: 75%
m.p.:181-182℃
[α] D 26:-128.39 ° (c=0.5, chloroform)
IR(Nujol,cm -1):2217,1755,1665,1615
MS(m/z):735(MH +)
NMR(300MHz,CDCl 3,δ):0.77(3H,t,J=7.5Hz),0.85(3H,s),0.89(3H,t,J=7Hz),1.20(3H,s),2.13(1H,dq,J=7.3?and?15Hz),2.27(1H,dq,J=7.3?and15Hz),2.52-2.57(2H,m),3.45-3.66(7H,m),3.80-3.90(1H,m),4.16(1H,dq,J=7.3?and?13Hz),4.36(1H,dq,J=7.3?and?13Hz),4.52(1H,d,J=15Hz),4.87(1H,d,J=15Hz),5.48(1H,dd,J=3?and?6Hz),6.85(1H,s),7.00-7.10(1H,m),7.12-7.23(3H,m),8.05(2H,d,J=9Hz),8.24(2H,d,J=9Hz)
(3) handle the compound that obtains in above (2) according to the same procedure described in embodiment 1-(3)-(8) or embodiment 1-(3)-(5), (7), (6) and (8), produce (20S)-7-ethyl-10-(the amino propoxy-of 3-) camptothecine hydrochloride.
Figure A20061010119200431
Embodiment 4
(1) with 2-bromo-2-[6-cyano group-1; 1-(2; 2-diethyl-trimethylenedioxy)-5-oxygen-1,2; 3; 5-tetrahydrochysene-7-indoles mile pyridine base] ethyl acetate (363mg), (3R)-N-(4-biphenyl sulfonyl)-1,2,3; 4-tetrahydrochysene-3-1-isoquinolinecarboxylic acid (472mg) and salt of wormwood (95mg) mix in dimethyl formamide (4ml), and stir this mixture 40 minutes down in 70 ℃.Handle this reaction mixture according to the same procedure described in the embodiment 1-(1); produce the 2-[[(3R of colourless powder shape)-N-(4-biphenyl sulfonyl)-1; 2,3,4-tetrahydrochysene-3-isoquinolyl] the ketonic oxygen base]-2-[6-cyano group-1; 1-(2; 2-diethyl-trimethylenedioxy)-5-oxygen-1,2; 3,5-tetrahydrochysene-7-indoles mile pyridine base] ethyl acetate (579mg).
Yield: 94%
Figure A20061010119200441
IR(Nujol,cm -1):2225,1750,1665,1615
MS(m/z):766(MH +)
NMR(300MHz,CDCl 3,δ):0.84(3H,t,J=7.5Hz),0.94(3H,t,J=7.5Hz),1.11?and1.16(3H,t,J=7Hz),1.20-1.30(2H,m),1.77-1.86(2H,m),2.45-2.60(2H,m),3.27-3.40(2H,m),3.60-3.65(2H,m),3.75-3.90(2H,m),4.00-4.20(4H,m),4.55?and4.80(2H,m),5.21?and?5.28(1H,dd,J=3?and?6Hz),6.02?and?6.06(1H,s),6.57and?6.63(1H,s),7.00-7.20(4H,m),7.40-7.70(7H,m),7.88?and?7.90(2H,d,J=8Hz)
(2) with 2-[[(3R)-N-(4-biphenyl sulfonyl)-1; 2; 3; 4-tetrahydrochysene-3-isoquinolyl] the ketonic oxygen base]-2-[6-cyano group-1, and 1-(2,2-diethyl-1; the inferior third dioxy base of 3-)-5-oxygen-1; 2,3,5-tetrahydrochysene-7-indoles mile pyridine base] ethyl acetate (564mg) is dissolved in the exsiccant dimethyl formamide (5ml); according to the same procedure described in the embodiment 1-(2); 60% oily dispersion and iodoethane (1150mg) (10 equivalent) with sodium hydride (35mg) (1.2 equivalent) make this mixture reaction, produce the 2-[[(3R of colourless powder shape)-N-(4-biphenyl sulfonyl-)-1,2; 3; 4-tetrahydrochysene-3-isoquinolyl] the ketonic oxygen base]-2-[6-cyano group-1, and 1-(2,2-diethyl-1; the inferior third dioxy base of 3-)-5-oxygen-1; 2,3,5-tetrahydrochysene-7-indoles mile pyridine base] ethyl butyrate (mixture of diastereomer) is (522mg).The cis-selectivity of 2S compound and 2R compound=10.8: 1.0 (83% d.e.), it is according to δ in the NMR spectrum: the ratio of the integrated value at 6.67 and 6.43 peaks calculates and gets.
IR(Nujol,cm -1):2220,1750,1660,1615
MS(m/z):794(MH +)
NMR(300MHz,CDCl 3,δ):0.69(3H,t,J=7.5Hz),0.81(3H,t,J=7.5Hz),0.87(3H,t,J=7.5Hz),1.03(3H,t,J=7Hz),1.22(2H,q,J=7.5Hz),1.67(2H,q,J=7.5Hz),2.20-2.45(4H,m),3.34(1H,dd,J=6.5?and?16Hz),3.48-3.58(3H,m),3.70-3.85(4H,m),3.98-4.10(2H,m),4.67(1H,d,J=15Hz),4.76(1H,d,J=15Hz),5.36(1H,dd,J=3?and?6.5Hz),6.43?and?6.67(1H,s),7.00-7.20(4H,m),7.40-7.50(3H,m),7.56(2H,d,J=8Hz),7.65(2H,d,J=9Hz),7.92(2H,d,J=9Hz)
(3) handle the compound that obtains in above (2) according to the same procedure described in embodiment 1-(3)-(8) or embodiment 1-(3)-(5), (7), (6) and (8), produce (20S)-7-ethyl-10-(the amino propoxy-of 3-) camptothecine hydrochloride.
Figure A20061010119200452
Embodiment 5
(1) will be in embodiment 1-(4) resulting (2S)-2-[[(3R)-N-(4-biphenyl sulfonyl-)-1; 2; 3,4-tetrahydrochysene-3-isoquinolyl] the ketonic oxygen base]-2-[6-acetyl-o-methyl-1,1-(2; 2-dimethyl-1; the inferior third dioxy base of 3-)-and 5-oxygen-1,2,3; 5-tetrahydrochysene-7-indoles mile pyridine base] ethyl butyrate (1.00g) is dissolved in water-methanol-tetrahydrofuran (THF) (5ml+20ml+5ml); add lithium hydroxide monohydrate (265mg), under room temperature, stirred this mixture 1 hour, produce (2S)-2-hydroxyl-2-[6-methylol-1; 1-(2; 2-dimethyl-trimethylenedioxy)-5-oxygen-1,2; 3,5-tetrahydrochysene-7-indoles mile pyridine base] the butyric acid lithium.
Figure A20061010119200461
(2) (the 2S)-2-hydroxyl-2-[6-methylol-1 that obtains more than the general, 1-(2,2-dimethyl-1, the inferior third dioxy base of 3-)-and 5-oxygen-1,2,3,5-tetrahydrochysene-7-indoles mile pyridine base] the butyric acid lithium is dissolved in chloroform (20ml) and the acetate (4ml), under room temperature, stirred this mixture 16 hours, water is added in this reaction mixture, and with this mixture of chloroform extraction 3 times.Wash this extracting solution with saturated brine liquid, through dried over sodium sulfate, reduction vaporization.Its resistates through re-crystallizing in ethyl acetate, produces colourless pin crystalline (4S)-7 with purification by silica gel column chromatography (elutriant chloroform), 8-dihydro-4-ethyl-6, and 6-(2,2-dimethyl-1, the inferior third dioxy base of 3-)-and also [3,4-f] the indoles mile pyridine-3 of 4-hydroxyl-1H-pyrans, 10-diketone (276mg).
Yield: the total recovery of above (1) and (2) is 64%
Figure A20061010119200462
m.p.:208-210℃
[α] D 27:+88.2 ° (c=0.99, chloroform)
IR(Nujol,cm -1):3340,2924,1744
MS(m/z):350(MH +)
NMR(300MHz,CDCl 3,δ):0.88(3H,s),0.99(3H,t,J=7.3Hz),1.29(3H,s),1.70-1.92(2H,m),2.54(2H,t,J=7.0Hz),3.65-3.69(4H,m),3.71(1H,s),4.14(2H,dt,J=3.7?and?7.0Hz),5.17(1H,d,J=16.2Hz),5.60(1H,d,J=16.2Hz),6.81(1H,s)
(3) handle (4S)-7 according to the same procedure described in the embodiment 1-(5), 8-dihydro-4-ethyl-6, and 6-(2,2-dimethyl-1, the inferior third dioxy base of 3-)-4-hydroxyl-1H-pyrans also [3,4-f] indoles mile pyridine-3, the 10-diketone produces (4S)-7,8-dihydro-4-ethyl-4-hydroxyl-1H-pyrans also [3,4-f] indoles mile pyridine-3,6,10 (4H)-triketones.
(4) handle (4S)-7 according to embodiment 1-(6) with the identical method described in (8), 8-dihydro-4-ethyl-4-hydroxyl-1H-pyrans is [3,4-f] indoles mile pyridine-3,6 also, 10 (4H)-triketones produce (20S)-7-ethyl-10-(the amino propoxy-of 3-) camptothecine hydrochloride.
Figure A20061010119200472
Embodiment 6
(1) handles (the 2S)-2-hydroxyl-2-[6-methylol-1 of gained in embodiment 5-(1) according to the same procedure described in the embodiment 1-(5), 1-(2,2-dimethyl-trimethylenedioxy)-5-oxygen-1,2,3,5-tetrahydrochysene-7-indoles mile pyridine base] the butyric acid lithium, produce (4S)-7,8-dihydro-4-ethyl-4-hydroxyl-1H-pyrans also [3,4-f] indoles mile pyridine-3,6,10 (4H)-triketones.
Figure A20061010119200481
(2) handle (4S)-7 according to embodiment 1-(6) with the identical method described in (8), 8-dihydro-4-ethyl-4-hydroxyl-1H-pyrans is [3,4-f] indoles mile pyridine-3,6 also, 10 (4H)-triketones produce (20S)-7-ethyl-10-(the amino propoxy-of 3-) camptothecine hydrochloride.
Embodiment 7
(1) (4S)-7 that embodiment 5-(2) is obtained, 8-dihydro-4-ethyl-6, and 6-(2,2-dimethyl-1, the inferior third dioxy base of 3-)-4-hydroxyl-1H-pyrans also [3,4-f] indoles mile pyridine-3,10-diketone (50mg) is dissolved in the diacetyl oxide (1ml), under ice-cooled, add pyridine (1ml) and 4-N, N-Dimethylamino pyridine (4mg), and under room temperature, stirred this mixture 23 hours.Dilute this reaction mixture with chloroform, wash this mixture with aqueous citric acid solution, water and saturated brine liquid, through dried over sodium sulfate.After under reduced pressure steaming desolventizes, its resistates purification by silica gel column chromatography (elutriant: chloroform: methyl alcohol=40: 1), produce (4S)-7 of colourless crystallization shape, 8-dihydro-4-ethyl-6,6-(2,2-dimethyl-trimethylenedioxy)-4-acetoxyl group-1H-pyrans also [3,4-f] indoles mile pyridine-3,10-diketone (56mg).
Yield: 99%
Figure A20061010119200483
m.p.:185-188℃
IR(Nujol,cm -1):2922,2852,1743,1671,1613
MS(m/z):392(MH +)
NMR(300MHz,CDCl 3,δ):0.87(3H,s),0.91(3H,t,J=7.5Hz),1.28(3H,s),1.95-2.10(1H,m),2.15(3H,s),2.15-2.28(1H,m),2.40-2.61(2H,m),3.55-3.73(4H,m),4.12(2H,t,J=6.8Hz),5.27(1H,d,J=17.1Hz),5.52(1H,d,J=17Hz),6.31(1H,s)
(2) handle (4S)-7 according to the same procedure described in the embodiment 1-(5), 8-dihydro-4-ethyl-6, and 6-(2,2-dimethyl-1, the inferior third dioxy base of 3-)-4-acetoxyl group-1H-pyrans also [3,4-f] indoles mile pyridine-3,10-diketone, (4S)-7 that produce the colourless crystallization shape, 8-dihydro-4-ethyl-4-acetoxyl group-1H-pyrans also [3,4-f] indoles mile pyridine-3,6,10 (4H)-triketones.
m.p.:197-203℃
IR(Nujol,cm -1):1742,1732,1661,1610
ESI-MS (0.02M ammonium acetate/methyl alcohol m/z): 323 (MNH 4 +)
NMR(300MHz,CDCl 3,δ):0.92(3H,t,J=7.5Hz),1.94-2.25(2H,m),2.16(3H,s),2.95(2H,t,J=6.9Hz),4.32(2H,td,J=6.9?and?0.8Hz),5.33(1H,dd,J=18.1?and0.5Hz),5.60(1H,dd,J=18.1?and?0.4Hz),6.76(1H,s)
(3) handle (4S)-7 according to the identical method described in the embodiment 1-(6); 8-dihydro-4-ethyl-4-acetoxyl group-1H-pyrans also [3; 4-f] indoles mile pyridine-3; 6; 10 (4H)-triketones, (20S)-20-O-ethanoyl-7-ethyl-10-[3-(tert-butoxycarbonyl-amino) propoxy-of generation colourless powder shape] camptothecine.
Figure A20061010119200492
m.p.:173-176℃
IR(Nujol,cm -1):3370,1765,1749,1696,1657
ESI-MS(m/z):592(MH +)
NMR(300MHz,CDCl 3,δ):0.97(3H,t,J=7.5Hz),1.39(3H,t,J=7.7Hz),1.45(9H,s),2.05-2.32(4H,m),2.21(3H,s),3.14(2H,q,J=7.7Hz),3.41(2H,q?like,J=6.3Hz),4.21(2H,t,J=6.1Hz),4.77(1H,br),5.23(2H,d,J=1.1Hz),5.40(1H,d,J=17.2Hz),5.68(1H,d,J=17.2Hz),7.15(1H,s),7.33(1H,d,J=2.6Hz),7.47(1H,dd,J=9.2?and?2.7Hz),8.12(1H,d,J=9.3Hz)
(4) handle (20S)-20-O-ethanoyl-7-ethyl-10-[3-(tert-butoxycarbonyl-amino) propoxy-according to embodiment 1-(7) with the identical method described in (8)] camptothecine, produce (20S)-7-ethyl-10-(the amino propoxy-of 3-) camptothecine hydrochloride.
Embodiment 8-12
(1) handle corresponding raw material according to the same procedure described in embodiment 1-(1) and (2), prepared compound is listed in the table below in 1.
Table 1
Figure A20061010119200511
(2) handle the compound that obtains in above (1) according to embodiment 1-(3)-(8) or embodiment 1-(3)-(5), (7), (6) and the identical method described in (8), produce (20S)-7-ethyl-10-(the amino propoxy-of 3-) camptothecine hydrochloride.
Embodiment 13-16
(1) handle corresponding raw material according to the same procedure described in embodiment 1-(1) and (2), prepared compound is listed in the table below in 2.
Table 2
Ts: tosyl group
(2) handle the compound that obtains in above (1) according to embodiment 1-(3)-(8) with embodiment 1-(3)-(5), (7), (6) and the identical method described in (8), produce (20S)-7-ethyl-10-(the amino propoxy-of 3-) camptothecine hydrochloride.
Embodiment 17-23
Handle corresponding raw material according to the same procedure described in embodiment 1,2,5 or 7, prepared compound is listed in the table below in 3.
Table 3
Figure A20061010119200531
*This numeral refers to the position of substitution (7-position/9-position) on the camptothecine parent nucleus.
Embodiment 24
(1) with 2-chloro-2-[6-cyano group-1; 1-(2; 2-dimethyl-1; the inferior third dioxy base of 3-)-and 5-oxygen-1,2,3; 5-tetrahydrochysene-7-indoles mile pyridine base] ethyl acetate (34.11g), (3R)-N-(4-biphenyl sulfonyl)-1; 2,3,4-tetrahydrochysene-3-1-isoquinolinecarboxylic acid (42.33g) and the mixture of salt of wormwood (8.67g) in dimethyl formamide (350ml) stirred 45 minutes down in 60 ℃.This reaction mixture with ice-cooled, with ethyl acetate (200ml) dilution, and is added saturated sodium bicarbonate aqueous solution (300ml), add entry (500ml) again.With this mixture of ethyl acetate extraction, its extracting solution is through washing, drying, usefulness activated carbon treatment and filtration.Steaming desolventizes; produce light yellow foamed 2-[[(3R)-N-(4-biphenyl sulfonyl-)-1; 2,3,4-tetrahydrochysene-3-isoquinolyl] the ketonic oxygen base]-2-[6-cyano group-1; 1-(2; 2-dimethyl-trimethylenedioxy)-5-oxygen-1,2; 3,5-tetrahydrochysene-7-indoles mile pyridine base] ethyl acetate (66.20g).
IR(Nujol,cm -1):2220,1750,1665,1615
MS(m/z):738(MH+)
NMR(300MHz,CDCl 3,δ):0.89?and?0.90(3H,s),1.10?and?1.15(3H,t,J=7Hz),1.33?and?1.35(3H,s),2.45-2.60(2H,m),3.25-3.40(2H,m),3.61-3.76(4H,m),3.95-4.22(4H,m),4.58?and?4.68(1H,d,J=16Hz),4.72?and?4.75(1H,d,J=16Hz),5.22?and?5.29(1H,dd?and?t,J=3.6?and?5Hz),6.01?and?6.04(1H,s),6.58?and6.65(1H,s),7.02-7.20(4H,m),7.37-7.51(3H,m),7.54-7.60(2H,m),7.62-7.68(2H,m),7.85-7.93(2H,m)
(2) handle the 2-[[(3R that obtains in above (1) according to the identical method described in embodiment 1-(2)-(8))-N-(4-biphenyl sulfonyl-)-1; 2; 3,4-tetrahydrochysene-3-isoquinolyl] the ketonic oxygen base]-2-[6-cyano group-1,1-(2; 2-dimethyl-1; the inferior third dioxy base of 3-)-and 5-oxygen-1,2,3; 5-tetrahydrochysene-7-indoles mile pyridine base] ethyl acetate, produce (20S)-7-ethyl-10-(the amino propoxy-of 3-) camptothecine hydrochloride.
With reference to embodiment 1
(1) with 6-cyano group-7-methyl isophthalic acid, 5-dioxy-1,2,3,5-tetrahydro indole mile pyridine (1.0g), 2,2-dimethyl-1, ammediol (6.64g) and tosic acid (15ml) mix in ethylene dichloride (25ml), use has the refluxing unit of Dean-Stark dewatering unit, under reflux state, and heating said mixture 17 hours.Wash this reaction mixture with saturated sodium bicarbonate aqueous solution and saturated brine solution, and through dried over mgso.After removing solvent under reduced pressure, its resistates purification by silica gel column chromatography (elutriant: chloroform: methyl alcohol=50: 1), through recrystallizing methanol, produce colourless pin crystalline 6-cyano group-7-methyl isophthalic acid, and 1-(2,2-dimethyl-1, the inferior third dioxy base of 3-)-5-oxygen-1,2,3,5-tetrahydro indole mile pyridine (1.05g).
Yield: 72%
m.p.:225-226℃
IR(Nujol,cm -1):2222,1645,1610
MS(m/z):275(MH +)
NMR(300MHz,CDCl 3,δ):0.87(3H,s),1.30(3H,s)2.49(3H,s),2.53(2H,t,J=7Hz),3.62(2H,d,J=11Hz),3.69(2H,d,J=11Hz),4.15(2H,t,J=7Hz),6.42(1H,s)
(2) 6-cyano group-7-methyl isophthalic acid, 1-(2,2-dimethyl-trimethylenedioxy)-5-oxygen-1,2,3,5-tetrahydro indole mile pyridine (14.43g) mixes in exsiccant toluene (300ml), adds 60% oily dispersion of sodium hydride (9.25g, 4.4 equivalents), on 80 ℃ heating bath, stirred this mixture 2 hours.Diethyl carbonate (24.85g, 4 equivalents) and ethanol (0.97g, 0.4 equivalent) are added in this reaction mixture, under 80 ℃, make this mixture reaction 3 hours.When this reaction mixture of cooling on ice bath, add 50% acetate (80ml).With this mixture of chloroform extraction, its extracting solution is washed with saturated salt, and through dried over mgso.After removing solvent under reduced pressure, its resistates purification by silica gel column chromatography (elutriant: chloroform: ethyl acetate=4: 1), through ethyl acetate-ether recrystallization, produce colourless pin crystalline 2-[6-cyano group-1, and 1-(2,2-dimethyl-1, the inferior third dioxy base of 3-)-5-oxygen-1,2,3,5-tetrahydrochysene-7-indoles mile pyridine base] ethyl acetate (14.63g).
Yield: 80%
m.p.:150-151℃
IR(Nujol,cm -1):2220,1725,1650,1610
MS(m/z):347(MH +)
NMR(300MHz,CDCl 3,δ):0.87(3H,s),1.28(3H,s),1.29(3H,t,J=7.5Hz),2.54(2H,t,J=7Hz),3.62(2H,d,J=11Hz),3.68(2H,d,J=11Hz),3.79(2H,s),4.16(2H,t,J=7Hz),4.22(2H,q,J=7Hz),6.54(1H,s)
(3) with 2-[6-cyano group-1,1-(2,2-dimethyl-1, the inferior third dioxy base of 3-)-5-oxygen-1,2,3,5-tetrahydrochysene-7-indoles mile pyridine base] ethyl acetate (14.60g) is added in the sodium hydride (2.02g in the exsiccant tetrahydrofuran (THF) (240ml), 1.2 in 60% oily dispersion equivalent), under room temperature, stirred this mixture 3 hours.Bromine (8.76g, 1.3 equivalents) is added in this reaction mixture, under room temperature, stirred this mixture 2 hours, add frozen water.With this mixture of chloroform extraction, wash this extracting solution with sodium thiosulfate solution and saturated brine liquid, and through dried over mgso.After under reduced pressure steaming desolventizes, its resistates purification by silica gel column chromatography (elutriant: chloroform: ethyl acetate=4: 1), through ethyl acetate-ether recrystallization, produce colourless pin crystalline 2-bromo-2-[6-cyano group-1, and 1-(2,2-dimethyl-1, the inferior third dioxy base of 3-)-5-oxygen-1,2,3,5-tetrahydrochysene-7-indoles mile pyridine base] ethyl acetate (15.66g).
Yield: 87%
m.p.:117-119℃
IR(Nujol,cm -1):2217,1725,1650,1610
MS(m/z):427(MH +)
NMR(300MHz,CDCl 3,δ):0.89(3H,s),1.28(3H,s),1.32(3H,t,J=7Hz),2.54(2H,t,J=7Hz),3.65(2H,d,J=12Hz),3.67(2H,d,J=12Hz),4.09-4.22(2H,m),4.24-4.35(2H,m),5.61(1H,s),6.90(1H,s)
With reference to embodiment 2
(1) with 6-cyano group-7-methyl isophthalic acid, 5-dioxy-1,2,3,5-tetrahydro indole mile pyridine (5.93g), 2,2-diethyl-1, ammediol (49.97g) and tosic acid (180ml) mix in ethylene dichloride (150ml), use has the refluxing unit of Dean-Stark dewatering unit, under reflux state, and heating said mixture 22 hours.Handle above-mentioned reaction mixture according to the identical method described in the reference embodiment 1-(1),, produce colourless pin crystalline 6-cyano group-7-methyl isophthalic acid through recrystallizing methanol, 1-(2,2-diethyl-trimethylenedioxy)-5-oxygen-1,2,3,5-tetrahydro indole mile pyridine (6.67g).
Yield: 70%
m.p.:197-198℃
IR(Nujol,cm -1):2219,1655,1610
MS(m/z):303(MH +)
NMR(300MHz,CDCl 3,δ):0.83(3H,t,J=7.5Hz),0.92(3H,t,J=7.5Hz),1.22(2H,q,J=7.5Hz),1.78(2H,q,J=7.5Hz),2.49(3H,s),2.52(2H,t,J=7Hz),3.64(2H,d,J=11Hz),3.78(2H,d,J=11Hz),4.14(2H,t,J=7Hz),6.39(1H,s)
(2) use 6-cyano group-7-methyl isophthalic acid, 1-(2,2-diethyl-trimethylenedioxy)-5-oxygen-1,2,3,5-tetrahydro indole mile pyridine (4.75g), exsiccant toluene (80ml), 60% oily dispersion of sodium hydride (2.76g, 4.4 equivalents), diethyl carbonate (7.42g, 4 equivalents) and ethanol (0.37ml, 0.4 equivalent), repetition is with reference to the process of embodiment 1-(2), and its product produces colourless pin crystalline 2-[6-cyano group-1 through ethyl acetate-ether recrystallization, 1-(2,2-diethyl-trimethylenedioxy)-5-oxygen-1,2,3,5-tetrahydrochysene-7-indoles mile pyridine base] ethyl acetate (3.71g).
Yield: 63%
m.p.:127-129℃
IR(Nujol,cm -1):2220,1745,1660,1605
MS(m/z):375(MH +)
NMR(300MHz,CDCl 3,δ):0.83(3H,t,J=7.5Hz),0.91(3H,t,J=7.5Hz),1.23(2H,q,J=7.5Hz),1.29(3H,t,J=7.5Hz),1.75(2H,q,J=7.5Hz),2.53(2H,t,J=7Hz),3.62(2H,d,J=12Hz),3.77(2H,d,J=12Hz),3.79(2H,s),4.15(2H,t,J=7Hz),4.22(2H,q,J=7Hz),6.50(1H,s)
(3) with 2-[6-cyano group-1,1-(2,2-diethyl-1, the inferior third dioxy base of 3-)-5-oxygen-1,2,3,5-tetrahydrochysene-7-indoles mile pyridine base] ethyl acetate (3.52g) is added in the sodium hydride (451mg in the exsiccant tetrahydrofuran (THF) (60ml), 1.2 in 60% oily dispersion equivalent), under room temperature, stirred this mixture 3 hours.With bromine (1.95g, 1.3 equivalent) add in this reaction mixture, under room temperature, stirred this mixture 3 hours, and handle this reaction mixture according to the same procedure described in the reference embodiment 1-(3), through ethyl acetate-ether recrystallization, produce colourless pin crystalline 2-bromo-2-[6-cyano group-1, and 1-(2,2-diethyl-1, the inferior third dioxy base of 3-)-5-oxygen-1,2,3,5-tetrahydrochysene-7-indoles mile pyridine base] ethyl acetate (2.45g).
Yield: 58%
m.p.:106-108℃
IR(Nujol,cm -1):2220,1735,1660,1610
MS(m/z):455(MH +)
NMR(300MHz,CDCl 3,δ):0.83(3H,t,J=7.5Hz),0.92(3H,t,J=7.5Hz),1.26(2H,q,J=7.5Hz),1.32(3H,t,J=7Hz),1.73(2H,q,J=7.5Hz),2.52(2H,t,J=7Hz),3.61(1H,d,J=12Hz),3.62(1H,d,J=12Hz),3.77(1H,dd,J=2?and?12Hz),3.80(1H,dd,J=2?and?12Hz),4.16(2H,m),4.25-4.35(2H,m),5.61(1H,s),6.85(1H,s)
With reference to embodiment 3
In sodium hydroxide (13.6g) water-soluble (300ml), with (3R)-1,2,3,4-tetrahydrochysene-3-1-isoquinolinecarboxylic acid (30.0g) is suspended in wherein, adds tetrahydrofuran (THF) (120ml).4-xenyl SULPHURYL CHLORIDE (42.9g) is added in the solution that is generated, under room temperature, stirred this mixture 1 hour.Under ice-cooled, this reaction mixture of the hcl acidifying with 10%, and dilute with water are used twice of ethyl acetate extraction then.Water and saturated brine solution are washed this extracting solution, through dried over sodium sulfate, use activated carbon treatment then.Remove by filter the insolubles in this extracting solution, and remove solvent under reduced pressure.Its resistates produces (the 3R)-N-(4-biphenyl sulfonyl)-1,2,3 of colourless crystallization shape, 4-tetrahydrochysene-3-1-isoquinolinecarboxylic acid (36.5g) through ethyl acetate-hexane recrystallization.
Yield: 55%
m.p.:195-202℃
[α] D 29:+8.02 ° (c=1.08, dimethyl formamide)
IR(Nujol,cm -1):3300,2924,1743,1456
MS(m/z):394(MH +)
NMR(300MHz,CDCl 3,δ):3.10-3.15(2H,m),4.48(1H,d,J=15.6Hz),4.67(1H,d,J=15.6Hz),4.93(1H,dd,J=4.0?and?5.3Hz),6.95-7.20(4H,m),7.40-7.53(3H,m),7.56-7.69(4H,m),7.83-7.88(2H,m)
With reference to embodiment 4
With (3R)-1,2,3,4-tetrahydrochysene-3-1-isoquinolinecarboxylic acid (5.32g) and sodium hydroxide (2.40g) add methylene dichloride-water (200ml: in mixture 200ml), under ice-cooled condition, with the solution of 30 minutes dropping 4-nitrobenzene sulfonyl chlorides (6.62g) in methylene dichloride (100ml).Stir this mixture 3 hours down ice-cooled, add sodium hydroxide (1.20g) and the solution of 4-nitrobenzene sulfonyl chloride (3.32g) in methylene dichloride (60ml) in order again.Stirred this mixture 2 hours down ice-cooled, and at room temperature, restir 17 hours dilutes this reaction mixture with chloroform and 10% hydrochloric acid.Collect its chloroform layer, water is washed with saturated brine solution then, through dried over sodium sulfate, uses activated carbon treatment then.Remove by filter insolubles from chloroform layer, remove solvent under reduced pressure.Its resistates through ethyl acetate-hexane recrystallization, produces (the 3R)-N-(4-oil of mirbane alkylsulfonyl)-1,2,3 of colourless crystallization shape, 4-tetrahydrochysene-3-1-isoquinolinecarboxylic acid (4.01g) with silica gel column chromatography (elutriant chloroform) purifying.
Yield: 37%
m.p.:140℃
[α] D 25:+27.2 ° (c=0.5, ethanol)
IR(Nujol,cm -1):3316,1743,1531,1169
MS(m/z):361(M-H +)
NMR(300MHz,CDCl 3,δ):3.15-3.30(2H,m),4.40(1H,d,J=15Hz),4.73(1H,d,J=15Hz),5.01(1H,dd,J=3.7?and?5.7Hz),7.04-7.20(4H,m),7.99(2H,d,J=9.0Hz),8.20(2H,d,J=9.0Hz)
With reference to embodiment 5
In the presence of argon gas, in-4 ℃ triethylamine (13.94g) is added 2-[6-cyano group-1,1-(2,2-dimethyl-1, the inferior third dioxy base of 3-)-and 5-oxygen-1,2,3,5-tetrahydrochysene-7-indoles mile pyridine base] in the suspension of ethyl acetate (43.41g) in tetrahydrofuran (THF) (600ml), also in-4 ℃ to-3 ℃ with dripping trimethylsilyl chloride (14.41g) in 5 minutes.Under uniform temp, stirred this mixture 55 minutes, and following in-4 ℃ to 4 ℃ with the suspension of 7 minutes dropping N-chloro-succinic diamides (17.00g) in tetrahydrofuran (THF) (400ml).In this reaction mixture of 0-4 ℃ of restir 4.5 hours, under 0 ℃, add entry (1 liter), with this mixture of ethyl acetate extraction.Its extracting solution is through washing, drying, usefulness activated carbon treatment, filtration, and steaming desolventizes then.Its resistates produces colourless pin crystalline 2-chloro-2-[6-cyano group-1,1-(2,2-dimethyl-trimethylenedioxy)-5-oxygen-1,2,3,5-tetrahydrochysene-7-indoles mile pyridine base through ethyl acetate-isopropyl ether recrystallization] ethyl acetate (40.28g).
Yield: 84%
m.p.:153-155℃
IR(Nujol,cm -1):2227,1749,1662,1615,1541,1311,1241,1202,1179,1161,1143,1065,967,835,715
APCIMS(m/z):381?and?383(MH +)
NMR(300MHz,CDCl 3,δ):0.88(3H,s),1.28(3H,s),1.31(3H,t,J=7.1Hz),2.52-2.58(2H,m),3.60-3.70(4H,m),4.13-4.21(2H,m),4.22-4.37(2H,m),5.63(1H,s),6.77(1H,s)
With reference to embodiment 6
(1) 3-aminopropanol (6.0g) is dissolved in the methylene dichloride (50ml), under ice-cooled and stirring, drips dimethyl dicarbonate butyl ester (18.3g).Under room temperature, stir this mixture 2 hours, concentrate this reaction mixture, use purification by silica gel column chromatography then, produce the 3-tert-butoxycarbonyl aminopropanol (13.98g) of colorless oil.
Yield: 99.9%
IR (pure product), v MaxCm -1: 3380,1790
MS(m/z):176(M+H +)
NMR(300MHz,CDCl 3,δ):1.45(9H,s),1.62-1.72(2H,m),3.0(1H,brs.),3.29(2H,dd,J=12Hz?and?6Hz),3.66(2H,dd,J=12Hz?and?6Hz),4.80(1H,brs)
(2) 3-tert-butoxycarbonyl aminopropanol (10.0g) is dissolved in (100ml) in the methylene dichloride, under ice-cooled and stirring, adds triethylamine (8.66g) and toluene sulfonyl chloride (16.3g).Its mixture stirs under room temperature and spends the night.Concentrate this reaction mixture, its resistates is water-soluble-ethyl acetate in, tell organic layer, wash with saturated brine solution, through dried over sodium sulfate, steam then and desolventize.With this resistates of purification by silica gel column chromatography, produce the amino propyl ester (15.37g) of tosic acid 3-tert-butoxycarbonyl of light yellow oily.
Yield: 82%
IR (pure product), v MaxCm -1: 3400,3340,1700,1600
MS(m/z):352(M+Na +)
NMR(300MHz,CDCl 3,δ):1.42(9H,s),1.78-1.90(2H,m),2.45(3H,s),3.11-3.22(2H,m),4.09(2H,t,J=6Hz),4.5-4.65(1H,m),7.36(2H,d,J=8Hz),7.77-7.83(2H,m)
(3) 5-hydroxyl-2-nitrobenzaldehyde (6.0g) is dissolved in the exsiccant tetrahydrofuran (THF) (90ml), in-78 ℃ and stir down, drips vinyl bromination magnesium (2.3 equivalent).The temperature of this reaction mixture gradually raises.After this reaction is finished, 1N HCl is added in this reaction mixture, with this mixture of ethyl acetate extraction, tell its organic layer, with the washing of saturated brine liquid, through dried over sodium sulfate, steaming desolventizes then.Its resistates purification by silica gel column chromatography produces the pulverous 1-of yellowish brown (5 '-hydroxyl-2 '-nitrophenyl)-2-propylene-1-alcohol (5.09g).
Yield: 73%
m.p.:126-130℃
IR(Nujol),v max?cm -1:3440,1600
MS(m/z):195(M +)
NMR(300MHz,CDCl 3,δ):2.4(1H,br),5.19(1H,dd,J=10.5Hz?and?1.5Hz),5.38(1H,dd,J=17Hz?and?1.5Hz),5.89(1H,m),6.08(1H,ddd,J=17Hz,10.5Hz?and5Hz),6.80(1H,dd,J=9Hz?and?3Hz),7.22(1H,d,J=3Hz),7.97(1H,d,J=9Hz),9.90(1H,brs)
(4) 1-(5 '-hydroxyl-2 '-nitrophenyl)-2-propylene-1-alcohol (2.0g) is dissolved in the exsiccant dimethyl formamide (100ml), adds the amino propyl ester (1.5 equivalent) of sodium iodide (1 equivalent), salt of wormwood and tosic acid 3-tert-butoxycarbonyl.Stir this mixture 6 hours down in 50 ℃, add ethyl acetate.Wash this mixture with saturated brine liquid, through dried over sodium sulfate.After steaming desolventizes, its resistates purification by silica gel column chromatography, the 1-[5 ' of generation light brown caramel shape (3 "-tert.-butoxy-carbonylamino propoxy-)-2 '-nitrophenyl]-2-propylene-1-alcohol (3.53g).
Yield: 98%
IR (pure product), v MaxCm -1: 3400,1690,1680
MS(m/z):375(M+Na +)
NMR(300MHz,CDCl 3,δ):1.44(9H,s),1.96-2.06(2H,m),2.80(1H,brs),3.33(2H,q,J=6.5Hz),4.11(2H,t,J=6Hz),4.8(1H,brs),5.24(1H,dd,J=10.5Hz?and1.5Hz),5.42(1H,dd,J=17Hz?and?1.5Hz),5.92(1H,d,J=5Hz),6.08(1H,ddd,J=17Hz,10.5Hz?and?5Hz),6.86(1H,dd,J=9Hz?and?3Hz),7.25(1H,d,J=3Hz),8.04(1H,d,J=9Hz)
(5) with 1-[5 ' (3 "-the amino propoxy-of tert-butoxycarbonyl)-2 '-nitrophenyl]-2-propylene-1-alcohol (9.66g) is dissolved in the chloroform (300ml), adds activated manganese dioxide (7.2g), this mixture of heating under reflux state.After finishing this reaction, with diatomite elimination inorganics, concentrate its filtrate, add ethyl acetate.Tell organic layer, wash, through dried over sodium sulfate with saturated brine solution.After steaming desolventized, its resistates was through purification by silica gel column chromatography, produced 1-[5 ' (3 "-the amino propoxy-of tert-butoxycarbonyl)-the 2 '-nitrophenyl of yellow crystal shape]-2-propylene-1-ketone (6.01g).
m.p.:65-71℃
Yield: 63%
IR (pure product), v MaxCm -1: 3350,1700
MS(m/z):351(M+H +)
NMR(300MHz,CDCl 3,δ):1.44(9H,s),1.98-2.18(2H,m),3.28-3.37(2H,q,J=6.5Hz),4.08-4.16(2H,m),4.67(1H,brs),5.85(1H,d,J=17.5Hz),6.02(1H,d,J=10.5Hz),6.62(1H,dd,J=17.5Hz?and?10.5Hz),6.82(1H,d,J=3Hz),7.03(1H,dd,J=9Hz?and?3Hz),8.17(1H,d,J=9Hz)
(6) with 1-[5 ' (3 "-the amino propoxy-of tert-butoxycarbonyl)-2 '-nitrophenyl]-2-propylene-1-ketone (325mg) is dissolved in the ethanol (15ml), adds palladium-carbon (40mg) of 10%, stirs this mixture 1.5 hours in hydrogen.After removing by filter this catalyzer, concentrate its filtrate, use purification by silica gel column chromatography, the 1-[5 ' of generation yellow powder shape (3 "-the amino propoxy-of tert-butoxycarbonyl)-2 '-aminophenyl] third-1-ketone (248mg).
m.p.:112-115℃
Yield: 83%
IR(Nujol),v max?cm -1:3450,3400,3340,1700,1650
MS(m/z):323(M+H +)
NMR(300MHz,CDCl 3,δ):1.21(3H,t,J=7Hz),1.45(9H,s),1.90-2.01(2H,m),2.95(2H,q,J=7.5Hz),3.33(2H,q,J=6.5Hz),3.97(2H,t,J=6.5Hz),4.48(1H,brs),5.96(2H,brs),6.62(1H,d,J=9Hz),6.95(1H,dd,J=9Hz?and?3Hz),7.24(1H,d,J=3Hz)

Claims (22)

1. the method that is used for preparation formula [VIII] S type 4-hydroxyl Pyranoindole mile acridine compound or its salt:
It comprises makes formula [VII] S type 4-type 4-substituted hydroxy-pyranindolelidinyl compounds remove R 0Base,
Figure A2006101011920002C2
Wherein, R 0For having the residue of the nitrogenous annelated heterocycles carboxylic acid of absolute configuration " R ", it is to remove (wherein, the nitrogen-atoms that contains is protected) that obtains behind the hydroxyl on the carboxyl by this carboxylic acid in described residue.
2. the method that is used for preparation formula [VIII] S type 4-hydroxyl Pyranoindole mile acridine compound or its salt:
It comprises makes mile pyridine base butyric ester compound for catalysis reduction of formula [II] S type 2-substituted hydroxy-2-indoles; so that reduce its cyano group; make it through alkanoylization then; production [V] S type 2-substituted hydroxy-2-(6-replaces aminomethyl indoles mile pyridine base) butyric ester compound; and make this compound [V] through nitrosation reaction and rearrangement; production [VI] S type 2-substituted hydroxy-2-(6-replaces skatoxyl mile pyridine base) butyric ester compound; make compound [VI] through the ester hydrolysis; production [IX] S type 2-hydroxyl-2-(6-skatoxyl mile pyridine base) butyric acid compound or its salt; make compound [IX] through intramolecular cyclization reaction; and thereafter or make its acetal radical change ketone group in this cyclization and optionally change its product into its salt, its Chinese style [II]; [V]; [VI] and [IX] is as follows:
Wherein, R 0For having the residue of the nitrogenous annelated heterocycles carboxylic acid of absolute configuration " R ", it is to remove (wherein, the nitrogen-atoms that contains is protected) that obtains behind the hydroxyl in described residue, R on the carboxyl by this carboxylic acid 1And R 2Be low alkyl group, reaching E is the ester residue,
Figure A2006101011920003C3
Wherein, R 3Be the lower alkane acyl group, and other symbol is as defined above,
Figure A2006101011920004C1
Wherein symbol as defined above,
Figure A2006101011920004C2
Wherein symbol as defined above.
3. the method that is used for preparation formula [XIII] S type 4-alkanoyloxy Pyranoindole mile acridine compound: it comprises makes mile pyridine base butyric ester compound for catalysis reduction of formula [II] S type 2-substituted hydroxy-2-indoles; so that reduce its cyano group; make it through alkanoylization then; production [V] S type 2-substituted hydroxy-2-(6-replaces aminomethyl indoles mile pyridine base) butyric ester compound; and make this compound [V] through nitrosation reaction and rearrangement; production [VI] S type 2-substituted hydroxy-2-(6-replaces skatoxyl mile pyridine base) butyric ester compound; make compound [VI] through the ester hydrolysis; production [IX] S type 2-hydroxyl-2-(6-skatoxyl mile pyridine base) butyric acid compound or its salt; make compound [IX] through intramolecular cyclization reaction; and optionally change its product into its salt; production [X] S type 4-hydroxyl Pyranoindole mile acridine compound or its salt; make the reaction of compound [X] or its salt and formula [XI] lower alkanols alkanoic acid or its derivatives reactivity; production [XII] S type 4-alkanoyloxy Pyranoindole mile acridine compound and make the acetal radical of compound [XII] change ketone group into, its Chinese style [XIII]; [II]; [V]; [VI]; [IX]; [X]; [XI] and [XII] is as follows:
Figure A2006101011920004C3
Wherein, R 4Be the lower alkane acyl group,
Figure A2006101011920005C1
Wherein, R 0For having the residue of the nitrogenous annelated heterocycles carboxylic acid of absolute configuration " R ", it is to remove (wherein, the nitrogen-atoms that contains is protected) that obtains behind the hydroxyl in described residue, R on the carboxyl by this carboxylic acid 1And R 2Be low alkyl group, reaching E is the ester residue,
Wherein, R 3Be the lower alkane acyl group, other symbol as defined above,
Wherein symbol as defined above,
Figure A2006101011920005C4
Wherein symbol as defined above,
Wherein symbol as defined above,
R 4OH [XI]
R wherein 4As defined above,
Wherein symbol as defined above.
4. the method that is used for preparation formula [XVI] Comptothecin compounds or its salt; it comprises makes formula [VII] S type 4-type 4-substituted hydroxy-pyranindolelidinyl compounds and the adjacent anilid compound reaction of formula [XIV]; production [XV] has substituent Comptothecin compounds on its 20 hydroxyls, make compound [XV] remove R 0Base, and work as R 5-R 9When group is protected, make it also remove protecting group, also optionally change it into salt, its Chinese style [XVI], [VII], [XIV] and [XV] are as follows:
Figure A2006101011920006C3
R wherein 51-R 91Group respectively is hydrogen atom or unprotected substituting group,
Figure A2006101011920007C1
Wherein, R 0For having the residue of the nitrogenous annelated heterocycles carboxylic acid of absolute configuration " R ", it is to remove (wherein, the nitrogen-atoms that contains is protected) that obtains behind the hydroxyl on the carboxyl by this carboxylic acid in described residue,
Figure A2006101011920007C2
Wherein, R 5-R 9Group is hydrogen atom or protection or unprotected substituting group,
Figure A2006101011920007C3
Wherein symbol as defined above.
5. the method that is used for preparation formula [XVI] Comptothecin compounds or its salt; it comprises makes formula [VIII] S type 4-hydroxyl Pyranoindole mile acridine compound or its salt and the adjacent anilid compound reaction of formula [XIV] that obtains in claim 1 or 2; production [XVII] Comptothecin compounds, and work as R 5-R 9When group is protected, make compound [XVII] remove protecting group, and optional its salt that further it changed into, its Chinese style [XVI], [VIII], [XIV] and [XVII] are as follows:
Figure A2006101011920008C1
Wherein, R 51-R 91Group respectively is hydrogen atom or unprotected substituting group,
Figure A2006101011920008C2
Wherein, R 5-R 9Group is hydrogen atom or protection or unprotected substituting group,
Wherein symbol as defined above.
6. the method that is used for preparation formula [XVI] Comptothecin compounds or its salt; it comprises makes formula [XIII] S type 4-chain acyl alkanoyloxy-Pyranoindole mile acridine compound and the adjacent anilid compound reaction of formula [XIV] that obtains in claim 3; production [XVIII] Comptothecin compounds, and make compound [XVIII] remove R 4Group is worked as R 5-R 9When group is protected, further make it remove protecting group, and optionally change it into its salt, its Chinese style [XVI], [XIII], [XIV] and [XVIII] are as follows:
Figure A2006101011920009C1
Wherein, R 51-R 91Be hydrogen atom or unprotected substituting group,
Figure A2006101011920009C2
R wherein 4Be the lower alkane acyl group,
Wherein, R 5-R 9Group is hydrogen atom or protection or unprotected substituting group,
Figure A2006101011920009C4
Wherein symbol as defined above.
7. according to the method for each claim among the claim 1-6, R wherein 0The residue that obtains for the hydroxyl of removing on the nitrogenous annelated heterocycles carboxylic acid of following formula [XIX] the R type carboxyl:
Figure A2006101011920010C1
Wherein Y replaces or unsubstituted aryl sulfonyl or alkyl sulphonyl, and n is 0 or 1.
8. according to the method for claim 7; wherein said substituting group " Y " is selected from benzenesulfonyl, naphthalene sulfonyl base or biphenyl sulfonyl (they are optional by nitro, low alkyl group, lower alkoxy, cycloalkyl, halogen atom or thiophene phenyl replacement) or low alkyl group alkylsulfonyl, and E is a low alkyl group.
9. according to the method for claim 7, wherein Y is 4-biphenyl sulfonyl or 4-nitrophenyl alkylsulfonyl, and n is 1, R 1And R 2Respectively be methyl, R 3Be ethanoyl, X is chlorine atom or bromine atoms, and E is methyl or ethyl.
10. formula [I] 2-substituted hydroxy-2-indoles mile pyridine yl acetate compound:
Wherein, R 0Be the residue of nitrogenous annelated heterocycles carboxylic acid with absolute configuration " R ", it is (wherein, nitrogen-atoms contained in this residue is protected) that obtains behind the hydroxyl by removing from the carboxyl of this carboxylic acid, R 1And R 2For low alkyl group and E are the ester residue.
11. formula [V] S type 2-substituted hydroxy-2-(6-replaces aminomethyl indoles mile pyridine base) butyric ester compound:
Wherein, R 0Be the residue of nitrogenous annelated heterocycles carboxylic acid with absolute configuration " R ", it is (wherein, nitrogen-atoms contained in this residue is protected) that obtains behind the hydroxyl by removing from the carboxyl of this carboxylic acid, R 1And R 2Be low alkyl group, E is ester residue and R 3Be the lower alkane acyl group.
12. have the compound of following formula:
Figure A2006101011920011C1
Wherein, R 0Be the residue of nitrogenous annelated heterocycles carboxylic acid with absolute configuration " R ", it is (wherein, nitrogen-atoms contained in this residue is protected) that obtains behind the hydroxyl by removing from the carboxyl of this carboxylic acid, R 1And R 2Be low alkyl group.
13. have substituent formula [XV] Comptothecin compounds on 20 hydroxyls:
Figure A2006101011920011C2
Wherein, R 0Be the residue of nitrogenous annelated heterocycles carboxylic acid with absolute configuration " R ", it is (wherein, nitrogen-atoms contained in this residue is protected) that obtains behind the hydroxyl by removing from the carboxyl of this carboxylic acid, and R 5-R 9Group is hydrogen atom or protection or unprotected substituting group.
14. have following formula [IX] S type 2-hydroxyl-2-(6-skatoxyl mile pyridine base) butyric acid compound or its salt:
R wherein 1And R 2Be low alkyl group.
15. have S type 4-hydroxyl Pyranoindole mile acridine compound or its salt of following formula [X]:
R wherein 1And R 2Be low alkyl group.
16. have the S type 4-alkanoyloxy Pyranoindole mile acridine compound of following formula [XII]:
R wherein 1And R 2Be low alkyl group, and R 4Be the lower alkane acyl group.
17. have the S type 4-chain acyloxy Pyranoindole mile acridine compound of following formula [XIII]:
R wherein 4Be the lower alkane acyl group.
18. have 2-halo-2-indoles mile pyridine yl acetate compound of following formula [III]:
Wherein, X is a halogen atom, R 1And R 2Be low alkyl group, reaching E is the ester residue,
19. have the indoles mile pyridine methylmethane compound of following formula [XXVI]:
Figure A2006101011920013C1
R wherein 1And R 2Be low alkyl group.
20. have the 2-indoles mile pyridine yl acetate compound of following formula [XXVIII]:
R wherein 1And R 2Be low alkyl group, E is the ester residue.
21. have the nitrogenous annelated heterocycles carboxylic acid of formula [XIX] or its salt of absolute configuration " R ":
Wherein Y replaces or unsubstituted aryl sulfonyl or alkyl sulphonyl, and n is 0 or 1.
22. have the Comptothecin compounds of formula [XVIII]:
Figure A2006101011920013C4
Wherein, R 4Be the lower alkane acyl group, and R 5-R 9Base is hydrogen atom or protection or unprotected substituting group.
CNB2006101011920A 1996-10-30 1997-10-30 S type 4-substituted hydroxy-pyranindolelidinyl compounds and its derivatives and production method Expired - Fee Related CN100528879C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP288074/1996 1996-10-30
JP28807496 1996-10-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNB011109580A Division CN100473654C (en) 1996-10-30 1997-10-30 S type 4-substituted hydroxypyranoindolidine compound and derivatives and preparation thereof

Publications (2)

Publication Number Publication Date
CN1915995A true CN1915995A (en) 2007-02-21
CN100528879C CN100528879C (en) 2009-08-19

Family

ID=17725479

Family Applications (3)

Application Number Title Priority Date Filing Date
CN97122529A Expired - Fee Related CN1077109C (en) 1996-10-30 1997-10-30 S type 2 -substituted hydroxy-2 -indolidinylbutyric ester compounds and process for preparation thereof
CNB011109580A Expired - Fee Related CN100473654C (en) 1996-10-30 1997-10-30 S type 4-substituted hydroxypyranoindolidine compound and derivatives and preparation thereof
CNB2006101011920A Expired - Fee Related CN100528879C (en) 1996-10-30 1997-10-30 S type 4-substituted hydroxy-pyranindolelidinyl compounds and its derivatives and production method

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN97122529A Expired - Fee Related CN1077109C (en) 1996-10-30 1997-10-30 S type 2 -substituted hydroxy-2 -indolidinylbutyric ester compounds and process for preparation thereof
CNB011109580A Expired - Fee Related CN100473654C (en) 1996-10-30 1997-10-30 S type 4-substituted hydroxypyranoindolidine compound and derivatives and preparation thereof

Country Status (14)

Country Link
US (7) US5932732A (en)
EP (3) EP1236728B1 (en)
KR (5) KR100474496B1 (en)
CN (3) CN1077109C (en)
AT (2) ATE332303T1 (en)
CA (2) CA2533685C (en)
DE (2) DE69724081T2 (en)
DK (2) DK1236728T3 (en)
ES (2) ES2267879T3 (en)
HK (2) HK1050356B (en)
ID (1) ID18747A (en)
PT (2) PT1236728E (en)
SG (4) SG104284A1 (en)
TW (1) TW464652B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113041841A (en) * 2021-03-22 2021-06-29 万华化学集团股份有限公司 Preparation method and application of anti-pollution concentrated water separation net

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG104284A1 (en) * 1996-10-30 2004-06-21 Tanabe Seiyaku Co S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds and process for preparation thereof
ATE413164T1 (en) 2000-11-09 2008-11-15 Neopharm Inc SN-38 LIPID COMPLEXES AND METHODS OF USE THEREOF
US20090137816A1 (en) * 2000-12-15 2009-05-28 Kurt Baum Process for the manufacture of diaminofurazan
US6350756B1 (en) 2001-01-18 2002-02-26 California Pacific Medical Center Camptothecin derivatives
TWI245768B (en) 2001-02-21 2005-12-21 Yakult Honsha Kk Process for synthesizing camptothecin related compound(s)
CN101337900B (en) * 2001-02-21 2013-12-18 株式会社雅库路特本社 Method of synthesizing camptothecin-relating compounds
US6855720B2 (en) 2001-03-01 2005-02-15 California Pacific Medical Center Nitrogen-based camptothecin derivatives
US6403604B1 (en) 2001-03-01 2002-06-11 California Pacific Medical Center Nitrogen-based camptothecin derivatives
WO2003030864A1 (en) * 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
WO2003101998A1 (en) * 2002-06-03 2003-12-11 California Pacific Medical Center Nitrogen-based homo-camptothecin derivatives
WO2003101406A1 (en) * 2002-06-03 2003-12-11 California Pacific Medical Center Homo-camptothecin derivatives
US20060030578A1 (en) * 2002-08-20 2006-02-09 Neopharm, Inc. Pharmaceutically active lipid based formulation of irinotecan
WO2004035032A2 (en) * 2002-08-20 2004-04-29 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
JP4433918B2 (en) * 2004-07-15 2010-03-17 コニカミノルタエムジー株式会社 Image forming method
KR100651728B1 (en) * 2004-11-10 2006-12-06 한국전자통신연구원 Compounds having anchoring group and electronic device including the same and methods for producing the same
CN100390177C (en) * 2004-11-25 2008-05-28 复旦大学 Preparation method of 6-cyano-7-methyl-1,1-(2,2-dimethyl-1,3-propylidine dioxy)-5-oxo-1,2,3,5-tetrahydro indolidin (I)
US7608740B2 (en) 2005-08-03 2009-10-27 Avra Laboratories Pvt. Ltd Method of synthesizing key intermediates for the production of camptothecin derivatives
US7875602B2 (en) * 2005-10-21 2011-01-25 Sutter West Bay Hospitals Camptothecin derivatives as chemoradiosensitizing agents
CN104341429B (en) * 2013-07-29 2016-08-10 北大方正集团有限公司 (S) preparation method of-camptothecine intermediate and the preparation method of (S)-camptothecine
EA202092410A1 (en) * 2018-04-06 2021-02-09 Сиэтл Дженетикс, Инк. CONJUGATES OF CAMPTOTHETCIN WITH PEPTIDE

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399282A (en) * 1979-07-10 1983-08-16 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives
JPS5711607A (en) * 1980-06-25 1982-01-21 Tokyo Shibaura Electric Co Movable shelf control apparatus
JPS57116074A (en) 1981-01-09 1982-07-19 Yakult Honsha Co Ltd Novel camptothecin derivative and its preparation
US4473692A (en) * 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
DE3682874D1 (en) * 1985-10-21 1992-01-23 Daiichi Seiyaku Co PYRANOINDOLICINE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF.
US4981968A (en) * 1987-03-31 1991-01-01 Research Triangle Institute Synthesis of camptothecin and analogs thereof
US5053512A (en) * 1987-04-14 1991-10-01 Research Triangle Institute Total synthesis of 20(S) and 20(R)-camptothecin and compthothecin derivatives
US5244903A (en) * 1987-03-31 1993-09-14 Research Triangle Institute Camptothecin analogs as potent inhibitors of topoisomerase I
US5122606A (en) * 1987-04-14 1992-06-16 Research Triangle Institute 10,11-methylenedioxy camptothecins
US4939255A (en) * 1987-06-24 1990-07-03 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic camptothecin derivatives
US4943579A (en) 1987-10-06 1990-07-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble prodrugs of camptothecin
JPH0615547B2 (en) * 1988-01-20 1994-03-02 株式会社ヤクルト本社 Novel camptothecin derivative
JP2524803B2 (en) * 1988-03-29 1996-08-14 株式会社ヤクルト本社 Novel camptothecin derivative and method for producing the same
ATE211142T1 (en) * 1989-09-15 2002-01-15 Res Triangle Inst METHOD FOR PRODUCING 10,11-METHYLENEDIOXY-20(RS)-CAMPTOTHECINE AND 10,11-METHYLENEDIOXY-20(S)-CAMPTOTHECIN ANALOG
TW201303B (en) * 1990-07-05 1993-03-01 Hoffmann La Roche
HU213136B (en) * 1990-08-14 1997-02-28 Kyorin Seiyaku Kk Process for producing fluoroethyl camptothecin derivatives and pharmaceutical compositions containing them
JP2923692B2 (en) * 1990-11-30 1999-07-26 第一製薬株式会社 Enzymatic resolution method
JP2887524B2 (en) * 1990-11-30 1999-04-26 第一製薬株式会社 Optical resolution method using microorganisms
JPH04210675A (en) * 1990-12-13 1992-07-31 Otsuka Pharmaceut Co Ltd Benzene derivative
DK0540099T3 (en) * 1991-10-29 1996-06-17 Glaxo Wellcome Inc Water-soluble camptothecin derivatives
EP0556585A3 (en) * 1992-01-24 1993-09-01 Takeda Chemical Industries, Ltd. Condensed camptothecin derivatives their production and use as antitumor agents
WO1993016698A1 (en) * 1992-02-21 1993-09-02 Smithkline Beecham Corporation SUBSTITUTED FURO[3',4':6,7]INDOLIZINO[1,2-b]QUINOLINONES
JP3126799B2 (en) * 1992-03-31 2001-01-22 第一製薬株式会社 Optically active camptothecin derivative and method for producing the same
JP3126798B2 (en) * 1992-03-31 2001-01-22 第一製薬株式会社 Optically active indolizine derivative and production method thereof
JP3359955B2 (en) * 1992-07-16 2002-12-24 第一製薬株式会社 Antitumor agent
IS4152A (en) * 1993-04-29 1994-10-30 Glaxo Inc. Water-soluble Camptothecin derivatives and their method of production
JPH07101956A (en) * 1993-10-05 1995-04-18 Tanabe Seiyaku Co Ltd Production of hydroxycamptothecin compound
KR960029336A (en) * 1995-01-09 1996-08-17 김충환 Camptothecin derivatives, preparation method thereof and anticancer agent containing same
IL117684A (en) * 1995-04-07 2002-02-10 Pharmacia & Upjohn Inc Intermediates and process for the manufacture of camptothesin derivatives (cpt-11) and related compounds
US5728712A (en) * 1995-05-19 1998-03-17 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
SG50747A1 (en) * 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
US6207672B1 (en) * 1995-11-13 2001-03-27 Aventis Pharma Deutschland Gmbh Cyclic and heterocyclic N-substituted α-iminohydroxamic and carboxyclic acids
WO1997019085A1 (en) 1995-11-22 1997-05-29 Research Triangle Institute Camptothecin compounds with combined topoisomerase i inhibition and dna alkylation properties
CA2192725C (en) * 1995-12-28 2004-04-20 Kenji Tsujihara Camptothecin derivatives
US5731316A (en) 1996-01-30 1998-03-24 The Stehlin Foundation For Cancer Research Derivatives of camptothecin and methods of treating cancer using these derivatives
SG104284A1 (en) * 1996-10-30 2004-06-21 Tanabe Seiyaku Co S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds and process for preparation thereof
DE19719817A1 (en) * 1997-05-13 1998-11-19 Hoechst Ag Substituted 6- and 7-aminotetrahydroisoquinoline carboxylic acids

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113041841A (en) * 2021-03-22 2021-06-29 万华化学集团股份有限公司 Preparation method and application of anti-pollution concentrated water separation net
CN113041841B (en) * 2021-03-22 2022-07-12 万华化学集团股份有限公司 Preparation method and application of anti-pollution concentrated water separation net

Also Published As

Publication number Publication date
US6716983B2 (en) 2004-04-06
CN100473654C (en) 2009-04-01
DE69724081T2 (en) 2004-06-09
CN1313286A (en) 2001-09-19
CA2533685A1 (en) 1998-04-30
PT1236728E (en) 2006-10-31
DE69736308T2 (en) 2007-06-14
EP0845464B1 (en) 2003-08-13
PT845464E (en) 2003-12-31
SG103322A1 (en) 2004-04-29
SG116433A1 (en) 2005-11-28
US6277992B1 (en) 2001-08-21
TW464652B (en) 2001-11-21
KR19980033318A (en) 1998-07-25
CA2533685C (en) 2009-05-26
DK1236728T3 (en) 2006-10-30
DK0845464T3 (en) 2003-12-01
EP1528062A3 (en) 2007-02-07
US20020161231A1 (en) 2002-10-31
EP0845464A2 (en) 1998-06-03
KR100567957B1 (en) 2006-04-05
HK1011538A1 (en) 1999-07-16
US6015901A (en) 2000-01-18
KR100578779B1 (en) 2006-05-12
KR20060086818A (en) 2006-08-01
SG88737A1 (en) 2002-05-21
KR100474496B1 (en) 2005-09-30
ATE247120T1 (en) 2003-08-15
CN100528879C (en) 2009-08-19
EP1236728B1 (en) 2006-07-05
MX9708343A (en) 1998-08-30
US6114529A (en) 2000-09-05
ES2205134T3 (en) 2004-05-01
EP1236728A3 (en) 2002-12-18
CA2219692A1 (en) 1998-04-30
CN1183414A (en) 1998-06-03
EP1236728A2 (en) 2002-09-04
DE69736308D1 (en) 2006-08-17
EP1528062A2 (en) 2005-05-04
HK1050356B (en) 2007-01-19
KR100525025B1 (en) 2005-10-31
ATE332303T1 (en) 2006-07-15
CA2219692C (en) 2007-05-22
CN1077109C (en) 2002-01-02
US6388078B1 (en) 2002-05-14
KR100653592B1 (en) 2006-12-05
DE69724081D1 (en) 2003-09-18
ES2267879T3 (en) 2007-03-16
EP0845464A3 (en) 1999-06-23
HK1050356A1 (en) 2003-06-20
SG104284A1 (en) 2004-06-21
US5932732A (en) 1999-08-03
US7060832B2 (en) 2006-06-13
ID18747A (en) 1998-05-07
US20030135049A1 (en) 2003-07-17

Similar Documents

Publication Publication Date Title
CN1915995A (en) S type 4-substituted hydroxy-pyranindolelidinyl compounds and its derivatives and production method
CN1036458C (en) Condensed heterocyclic compouds, their production and use
CN1084748C (en) Aminomethyl-2,3,8,9-tetrahydro-7H-1,4-dioxino[2,3-e]-indol-8-ones and derivatives
CN1241926C (en) Novel intermediate for preparing camptothecin derivative (CPT-11) and correlated compound and method thereof
CN1094038A (en) The amino pyrazoles that replaces
CN1235596A (en) Cyclic amine derivatives
CN1060841A (en) Quinazoline derivant and preparation method thereof
CN1038811A (en) 1-benzopyran derivatives and preparation method thereof
CN1043766C (en) Indole derivative and preparation and pharmaceutical using of same
CN1049500A (en) Benzopyran compounds, its production method and pharmaceutical composition
CN1111630A (en) Adhesion receptor antagonists
CN1082964C (en) Novel chiral bisphosphines
CN1249066C (en) 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
CN1086817A (en) Chromene and benzo-oxazine derivative
CN1327976A (en) Benzoxazinone compounds asymmetrically synthesized from new intermediate
CN1275966C (en) Pyrido-pyrido-pyrrolo pyrrolo-indole and pyrido-pyrrolo pyrrolo carbazole derivatives, method for prodn. thereof and pharmaceutical compsns. contg. said derivatives
CN1247590C (en) Process for synthesis of derivatives of 2,30dihydro-1,4-dioxino-[2,3-f]quinoline
CN1037895A (en) Hetera-aliphatic carboxamides
CN1138583A (en) 9-substituted 2-(2-n-alkoxyphenyl)-purin-6-ones
CN1068821A (en) Chroman derivatives
CN1192014C (en) Method for preparing HIV protease inhibitor
CN1798726A (en) Substituted indoles and a process for preparing substituted indoles
CN1186344C (en) Amino acid derivatives and use thereof as NEP, ACE and ECE inhibitors
CN1630555A (en) Hydroxylation of beta-dicarbonyls with zirconium catalysts
CN1099752A (en) Novel amidoalkyl- and imidoalkyl-piperazines

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: TANABE MITSUBISHI PHARMACEUTICAL CO.

Free format text: FORMER OWNER: TANADE SEIYAKU CO., LTD.

Effective date: 20080606

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20080606

Address after: Japan Osaka City Plaza Osaka built town 3 chome 2 No. 10

Applicant after: Mitsubishi Tanabe Pharma Corporation

Address before: Japan Osaka City Plaza Osaka built town 3 chome 2 No. 10

Applicant before: Tanabe Seiyaku Co., Ltd.

C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090819

Termination date: 20091130